Replacing the complementarity-determining regions in a human antibody with those from a mouse View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1986-05

AUTHORS

Peter T. Jones, Paul H. Dear, Jefferson Foote, Michael S. Neuberger, Greg Winter

ABSTRACT

The variable domains of an antibody consist of a beta-sheet framework with hypervariable regions (or complementarity-determining regions--CDRs) which fashion the antigen-binding site. Here we attempted to determine whether the antigen-binding site could be transplanted from one framework to another by grafting the CDRs. We substituted the CDRs from the heavy-chain variable region of mouse antibody B1-8, which binds the hapten NP-cap (4-hydroxy-3-nitrophenacetyl caproic acid; KNP-cap = 1.2 microM), for the corresponding CDRs of a human myeloma protein. We report that in combination with the B1-8 mouse light chain, the new antibody has acquired the hapten affinity of the B1-8 antibody (KNP-cap = 1.9 microM). Such 'CDR replacement' may offer a means of constructing human monoclonal antibodies from the corresponding mouse monoclonal antibodies. More... »

PAGES

522-525

Journal

TITLE

Nature

ISSUE

6069

VOLUME

321

Related Patents

  • Hybrid Antibodies
  • A Blocking Monoclonal Antibody To The Human Alpha1 I-Domain Of Vla-1, And Its Use For The Treatment Of Inflammatory Disorders
  • Super Humanized Antibodies
  • Nucleic Acids Encoding Humanized Anti-Tag 72 Cc49 Antbodies
  • Targeted Gene Delivery To Non-Phagocytic Mammalian Cells Via Bacterially Derived Intact Minicells
  • Compositions And Methods For Cancer
  • Growth Factor Binding Constructs Materials And Methods
  • Artificial Antibody Polypeptides
  • Bh3 Peptides And Method Of Use Thereof
  • Cd16a Binding Proteins And Use For The Treatment Of Immune Disorders
  • Luca2 And Antibodies That Bind Thereto
  • Materials And Methods For Improved Immunoglycoproteins
  • Therapy Targeting Flt4 (Veger-3) Expressed In Blood Vessels
  • Gitr-Binding Antibodies
  • Recombinant Tumor Specific Antibody And Use Thereof
  • Methods For Chemically Synthesizing Immunoglobulin Chimeric Proteins
  • Glycolipopeptide Antibodies
  • Human Monoclonal Antibodies To Ctla-4
  • Antibodies Directed Against Amyloid-Beta Peptide And Methods Using Same
  • Enhancing The Circulating Half-Life Of Antibody-Based Fusion Proteins
  • Estrogen Receptors And Methods Of Use
  • Tes7 And Antibodies That Bind Thereto
  • Methods Of Screening For Trpm5 Modulators
  • Antibodies To Vla-1
  • Method Of Isolating Cytotoxic Heterocomplex Associated With Multiple Sclerosis
  • Compositions For Treating Amyloid Associated Diseases
  • Compositions And Methods For Treatment Of Cancer
  • Syndecans And Angiogenesis
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Fully Human Antibodies Against Human 4-1bb
  • Antibodies To Il-17a
  • Cd44 Polypeptides, Polynucleotides Encoding Same, Antibodies Directed Thereagainst And Method Of Using Same For Diagnosing And Treating Inflammatory Diseases
  • Nucleic Acids Encoding Anti-Factor D Antibodies
  • Multispecific Antibodies
  • Anti-Cd151 Antibodies And Their Use In The Treatment Of Cancer
  • Deimmunized Serum-Binding Domains And Their Use For Extending Serum Half-Life
  • Multiple Signaling Pathways Induced By Hexavalent, Monospecific And Bispecific Antibodies For Enhanced Toxicity To B-Cell Lymphomas And Other Diseases
  • Methods For Treating Obesity Using Fibroblast Growth Factor-Like Polypeptides
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Klebsiella Antigens
  • Apo-2 Receptor Polypeptides
  • Humanized Anti-Prostate Stem Cell Antigen Monoclonal Antibody
  • Adam-9 Modulators
  • Microporous Materials, Methods, And Articles For Localizing And Quantifying Analytes
  • Recombinant Glycoproteins Related To Feline Thyrotropin
  • Variants Of Humanized Anti-Carcinoma Mab Cc49
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Inhibitors Of The Epidermal Growth Factor Receptor-Heat Shock Protein 90 Binding Interaction
  • Binding Domain-Immunoglobulin Fusion Proteins
  • Ephb3-Specific Antibody And Uses Thereof
  • Vitamin D-Ghrelin Conjugates
  • Antibodies And Pharmaceutical Compositions Containing Same Useful For Inhibiting Activity Of Metalloproteins
  • Porphyromonas Gingivalis Polypeptides Useful In The Prevention Of Periodontal Disease
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Therapeutic Use Of Anti-Cd22 Antibodies For Inducing Trogocytosis
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Dendritic Cell Marker And Uses Thereof
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Antibodies That Specifically Block The Biological Activity Of Kidney Associated Antigen 1 (Kaag1)
  • Antibodies Directed Against Amyloid-Beta Peptide And Methods Using Same
  • Antibody And Use Thereof
  • Methods Of Screening For Neoplastic Disease States
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or Anti-Adm Non-Ig Scaffold For Prevention Or Reduction Of Organ Dysfunction Or Organ Failure In A Patient Having A Chronic Or Acute Disease Or Acute Condition
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or Anti-Adm Non-Ig Scaffold For Regulating The Fluid Balance In A Patient Having A Chronic Or Acute Disease
  • Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
  • Method Of Screening For Compounds That Disaggregate Amyloid Aggregates
  • Interleukin-13 Binding Proteins
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Variant Hypocrea Jecorina Cbh1 Cellulase
  • Bgl7 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Clotting Factor-Fc Chimeric Proteins To Treat Hemophilia
  • Human Rhinovirus (Hrv) Antibodies
  • Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation
  • Simultaneous Imaging, Monitoring, And Therapy
  • Humanized Antibodies
  • Antibodies With Increased Binding Affinity
  • Antibody-Sn-38 Immunoconjugates With A Cl2a Linker
  • Compositions Comprising Anti-Ceacam1 And Anti-Pd Antibodies For Cancer Therapy
  • Factor Ix/Factor Ixa Activating Antibodies And Antibody Derivatives
  • Bgl4 Β-Glucosidase And Nucleic Acids Encoding The Same
  • Chimeric Antibody With Specificity To Human B Cell Surface Antigen
  • Egvi Endoglucanase And Nucleic Acids Encoding The Same
  • Methods For Treating Progressive Multiple Sclerosis
  • Therapeutic Combination And Methods Of Treatment With A Dll4 Antagonist And An Anti-Hypertensive Agent
  • Constructs Targeting Afp Peptide/Mhc Complexes And Uses Thereof
  • Matrix Metalloproteinases
  • Apo-2 Ligand
  • Substitutional Variants Of Apo-2 Ligand
  • Anti-Psca Antibodies
  • Antibodies To Dcr3 Polypeptide, A Tnfr Homolog
  • Monoclonal Antibodies Against Human Protein Mcm3, Process For Their Production, And Their Use
  • Multiple Cytokine Protein Complexes
  • Regulation Of Endogenous Gene Expression In Cells Using Zinc Finger Proteins
  • Anti-Cd4 Antibody Homologs Useful In Prophylaxis And Treatment Of Aids, Arc And Hiv Infection
  • Methods Of Blocking T-Cell Activation Using Anti-B7 Monoclonal Antibodies
  • Treatment For Inflammatory Bowel Disease With Vla-4 Blockers
  • Interleukin-5 Specific Recombinant Antibodies
  • Monoclonal Antibodies Against Tumor-Associated Antigens, Processes For The Preparation Thereof And The Use Thereof
  • Humanized Immunoglobulins And Methods Of Making The Same
  • Heterodimeric Antibodies To Cd3 X Cd123
  • Methods Of Delivering Dll3 Antibody Drug Conjugates
  • Interleukin-13 Binding Proteins
  • Monoclonal Antibody Capable Of Binding Integrin Alpha 10 Beta 1
  • Compositions Comprising Anti-Ceacam1 And Anti-Pd Antibodies For Cancer Therapy
  • Automatic Image Playback
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Method Of Screening For Compounds That Disaggregate Amyloid Aggregates
  • Dendritic Cell Marker And Uses Thereof
  • Interleukin-13 Binding Proteins
  • Antibodies That Specifically Block The Biological Activity Of Kidney Associated Antigen 1 (Kaag1)
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Methods For Treating Obesity Using Fibroblast Growth Factor-Like Polypeptides
  • Humanized Anti-Prostate Stem Cell Antigen Monoclonal Antibody
  • Antibody And Use Thereof
  • Methods Of Screening For Neoplastic Disease States
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Variant Hypocrea Jecorina Cbh1 Cellulase
  • Bgl7 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Compositions And Methods For Treatment Of Cancer
  • Adam-9 Modulators
  • Recombinant Glycoproteins Related To Feline Thyrotropin
  • Microporous Materials, Methods, And Articles For Localizing And Quantifying Analytes
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Porphyromonas Gingivalis Polypeptides Useful In The Prevention Of Periodontal Disease
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Antibodies And Pharmaceutical Compositions Containing Same Useful For Inhibiting Activity Of Metalloproteins
  • Human Rhinovirus (Hrv) Antibodies
  • Binding Domain-Immunoglobulin Fusion Proteins
  • Ephb3-Specific Antibody And Uses Thereof
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Inhibitors Of The Epidermal Growth Factor Receptor-Heat Shock Protein 90 Binding Interaction
  • Therapeutic Use Of Anti-Cd22 Antibodies For Inducing Trogocytosis
  • Vitamin D-Ghrelin Conjugates
  • Anti-Interferon-Α Antibodies
  • Humanized Chimeric Anti-Icam-1 Antibodies, Methods Of Preparation And Use
  • Humanised Antibodies
  • Methods For Inhibiting The Binding Of Endosialin To Ligands
  • Methods For Treating Bone Cancer Pain By Administering A Nerve Growth Factor Antagonist
  • Bgl7 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Cell Migration Assay
  • Method For Identifying Active Domains And Amino Acid Residues In Polypeptides And Hormone Variants
  • Humanized Antibodies
  • Dual Specific Binding Proteins Directed Against Il-1 And/Or Il-17
  • Cdna Encoding A Gene Bog (B5t Over-Expressed Gene) And Its Protein Product
  • Binding Proteins For Recognition Of Dna
  • Bgl5 Β-Glucosidase And Nucleic Acids Encoding The Same
  • Extracellular Matrix Metalloproteinase Inducer (Emmprin) Peptides And Binding Antibodies
  • Single-Chain Antibodies And Other Heteromultimers
  • Anti-Hepcidin Antibodies And Uses Thereof
  • Diagnostic Antibody Assay
  • Therapeutic Compositions For The Treatment Of Dry Eye Disease
  • Compositions And Methods For Targeted In Vitro And In Vivo Drug Delivery To Mammalian Cells Via Bacterially Derived Intact Minicells
  • M-Csf Specific Monoclonal Antibody And Uses Therof
  • Use Of Antibodies Against Specific Mhc-Peptide Complexes
  • Humanized Antibodies
  • Humanized Anti-Βantibodies
  • Human Type Complementarity Determining Region Transplantation Antibody Against Ganglioside Gd3 And Derivatives Of Antibody Against Ganglioside Gd3
  • Pd-1 Specific Antibodies And Uses Thereof
  • Tgf-Beta-Specific Antibodies And Methods Of Use Thereof For Treatment
  • Agr2 Blocking Antibody And Use Thereof
  • Polynucleotides Encoding Vegf/Dll4 Binding Agents
  • Composition And Method For The Diagnosis And Treatment Of Diseases Associated With Neurite Degeneration
  • Cd37 Immunotherapeutic And Combination With Bifunctional Chemotherapeutic Thereof
  • Anti-T. Cruzi Antibodies And Methods Of Use
  • Anti-Dll4/Vegf Dual Variable Domain Immunoglobulin And Uses Thereof
  • Pseudomonas Exotoxin A With Less Immunogenic T Cell And/Or B Cell Epitopes
  • Anti-Cancer Compounds And Methods For Treating Cancer
  • Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation
  • Bioconjugated Nanoparticles
  • Snow Mountain Virus Genome Sequence, Virus-Like Particles And Methods Of Use
  • Polypeptides And Polynucleotides For Artemin And Related Ligands, And Methods Of Use Thereof
  • Method For Multiple Chemokine Receptor Screening For Antagonists Using Ram Assay
  • Gamma-1 And Gamma-3 Anti-Human Cd23 Monoclonal Antibodies And Use Thereof As Therapeutics
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Il-1 Binding Proteins
  • Chimeric Ospa Proteins And Methods Of Use Thereof
  • Enzymatic Conjugation Of Polypeptides
  • Chimeric Antibody With Specificity To Human B Cell Surface Antigen
  • Human Growth Hormone Variants Having Greater Affinity For Human Growth Hormone Receptor At Site 1
  • Humanized Immunoglobulins
  • Growth Hormone Variants With Altered Binding Properties
  • Use Of Dr6 And P75 Antagonists To Promote Survival Of Cells Of The Nervous System
  • Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
  • Anti-Clusterin Antibodies And Antigen Binding Fragments And Their Use To Reduce Tumor Volume
  • Cadherin-11 Inhibitors And Methods Of Use Thereof
  • Cbh1 Homologs And Varian Cbh1 Cellulase
  • Methods For Enhanced Protein Production
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Glycopeptide And Uses Thereof
  • Il-1 Binding Proteins
  • Method Of Forming A Fiber Made Of Peptide Nanostructures
  • Nucleic Acid Molecules That Encode Human Anti-Ifn-Gamma Neutralizing Antibodies As Selective Ifn-Gamma Pathway Inhibitors
  • Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells
  • Pegylation Of Recombinant Blood Coagulation Factors In The Presence Of Bound Antibodies
  • Cd44 Polypeptides, Polynucleotides Encoding Same, Antibodies Directed Thereagainst And Method Of Using Same For Diagnosing And Treating Inflammatory Diseases
  • Targeted Delivery To Legumain-Expressing Cells
  • Detection And Modulation Of Cancer Stem Cells
  • Infectious Clone Of Human Parvovirus B19 And Methods
  • Monoclonal Antibodies That Bind B7h6 And Uses Thereof
  • Humanized Antibodies Against Cxcr3
  • Methods And Compositions For The Generation And Use Of Conformation-Specific Antibodies
  • Antibody-Sn-38 Immunoconjugates With A Cl2a Linker
  • Covalent Diabodies And Uses Thereof
  • Isolation, Detection, Diagnosis And/Or Characterization Of Circulating Trop-2-Positive Cancer Cells
  • Covalent Diabodies And Uses Thereof
  • Fgf21 Polypeptides Comprising Two Or More Mutations
  • Pd-1 Specific Antibodies And Uses Thereof
  • Modulation Of Enos Activity And Therapeutic Uses Thereof
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Dosages For Treatment With Anti-Erbb2 Antibodies
  • Vertebrate Smoothened Antibodies
  • Method For Making Humanized Antibodies
  • Method For Treating Ige-Mediated Disorders
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Multianalyte Assay
  • Labeling And Detection Of Post Translationally Modified Proteins
  • Polarization Sensitive Optical Coherence Tomography System
  • Humanized Anti-Βantibodies
  • Modified Vaccinia Ankara Expressing P53 In Cancer Immunotherapy
  • Complementarity Determining Region-Grafted Antibody Against Ganglioside Gd3 And Derivative Of Antibody Against Ganglioside Gd3
  • Humanised Antibodies
  • Cdna Encoding A Gene Bog (B5t Over-Expressed Gene) And Its Protein Product
  • Methods And Means For The Production Of Ig-Like Molecules
  • Humanized Anti-Beta7 Antagonists And Uses Therefor
  • Peptide Inhibitors Of Bace1
  • Bgl7 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Anti-Dll3 Antibodies
  • Antibody Variants With Enhanced Complement Activity
  • Composition And Method For The Diagnosis And Treatment Of Diseases Associated With Neurite Degeneration
  • Cd37 Immunotherapeutic And Combination With Bifunctional Chemotherapeutic Thereof
  • Anti-T. Cruzi Antibodies And Methods Of Use
  • Enzymatic Conjugation Of Polypeptides
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Automatic Stent Detection
  • Ddr1-Binding Agents And Methods Of Use Thereof
  • Humanized Immunoglobulins
  • Growth Hormone Variants With Altered Binding Properties
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Human Growth Hormone Variants Having Greater Affinity For Human Growth Hormone Receptor At Site 1
  • Anti-Dll3 Antibody Drug Conjugates
  • Gdf-15 As A Diagnostic Marker For Melanoma
  • Combination Therapy Using Inhibitors Of Human Growth And Differentiation Factor 15 (Gdf-15) And Immune Checkpoint Blockers
  • Treatment And Prevention Of Cancer With Hmgb1 Antagonists
  • Polypeptides And Polynucleotides For Artemin And Related Ligands, And Methods Of Use Thereof
  • Method For Multiple Chemokine Receptor Screening For Antagonists Using Ram Assay
  • Snow Mountain Virus Genome Sequence, Virus-Like Particles And Methods Of Use
  • Anti-Pd-L1 Antibodies, Compositions And Articles Of Manufacture
  • Tgf-Beta-Specific Antibodies And Methods Of Use Thereof For Treatment
  • Agr2 Blocking Antibody And Use Thereof
  • Polynucleotides Encoding Vegf/Dll4 Binding Agents
  • Chimeric Antibody With Specificity To Human B Cell Surface Antigen
  • Anti-Dll4/Vegf Dual Variable Domain Immunoglobulin And Uses Thereof
  • Il-1 Binding Proteins
  • Chimeric Ospa Proteins And Methods Of Use Thereof
  • Methods And Assays For Measuring P95 And/Or P95 Complexes In A Sample And Antibodies Specific For P95
  • Immunocytokine Sequences And Uses Thereof
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Single Chain Multivalent Binding Proteins With Effector Function
  • Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation
  • Targeted Cryptosporidium Biocides
  • Antibody Variants
  • Compositions And Methods For Diagnosing And Treating Phenylketonuria (Pku)
  • Recombinant Human Anti-Cd18 Antibodies
  • Rapid Clearance Of Antigen Complexes Using Novel Antibodies
  • Antibodies With Modified Isoelectric Points
  • Methods For Generating Radioimmunoconjugates
  • Vessel Assembly
  • Anti Il-6r Polypeptides And Compositions Thereof
  • Human Monoclonal Antibodies To Ctla-4
  • Immunoglobulins Insertions, Deletions, And Substitutions
  • Immunoglobulin Insertions, Deletions, And Substitutions
  • Production Of Proteins In Glutamine-Free Cell Culture Media
  • Interleukin-13 Binding Proteins
  • Antibodies To Il-17a
  • Telescopic Side Port Catheter Device With Imaging System And Method For Accessing Side Branch Occlusions
  • Method For Inducing Cell Death In Acute Lymphoblastic Leukemic System Cells
  • Systems For Correcting Distortions In A Medical Image And Methods Of Use Thereof
  • Gamma-1 And Gamma-3 Anti-Human Cd23 Monoclonal Antibodies And Use Thereof As Therapeutics
  • Glycopeptide And Uses Thereof
  • Il-1 Binding Proteins
  • Isolated B7-H4 Specific Compositions And Methods Of Use Thereof
  • Position Dependent Recognition Of Gnn Nucleotide Triplets By Zinc Fingers
  • Anti-Idiotypic Antibody Neutralizing The Inhibitor Activity Of A Factor Viii Inhibitor Antibody
  • Method Of Forming A Fiber Made Of Peptide Nanostructures
  • Use Of Dr6 And P75 Antagonists To Promote Survival Of Cells Of The Nervous System
  • Human Anti-Opgl Neutralizing Antibodies As Selective Opgl Pathway Inhibitors
  • Antibody-Drug Conjugates And Uses Thereof
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Compositions And Methods For Simultaneous Bivalent And Monovalent Co-Engagement Of Antigens
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Stimulus Responsive Polymers For The Purification Of Biomolecules
  • Substances And Their Uses
  • Method For Making Humanized Antibodies
  • Nucleic Acid Molecules That Encode Human Anti-Ifn-Gamma Neutralizing Antibodies As Selective Ifn-Gamma Pathway Inhibitors
  • Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells
  • Pegylation Of Recombinant Blood Coagulation Factors In The Presence Of Bound Antibodies
  • Anti-Clusterin Antibodies And Antigen Binding Fragments And Their Use To Reduce Tumor Volume
  • Dosages For Treatment With Anti-Erbb2 Antibodies
  • Vertebrate Smoothened Antibodies
  • Method For Making Humanized Antibodies
  • Modulation Of Enos Activity And Therapeutic Uses Thereof
  • Camptothecin Conjugates Of Anti-Cd22 Antibodies For Treatment Of B Cell Diseases
  • Antibodies To Receptor For Advanced Glycation End Products (Rage) And Uses Thereof
  • Antibodies That Bind Il-4 And/Or Il-13 And Their Uses
  • Assays For Detecting Antibodies Specific To Therapeutic Anti-Ige Antibodies And Their Use In Anaphylaxis
  • Peptide Inhibitors Of Bace1
  • Anti-Dll3 Antibodies
  • Antibody Variants With Enhanced Complement Activity
  • Method For Making Humanized Antibodies
  • Production Of Chimeric Antibodies With Specificity To Human Tumor Antigens
  • Humanized Anti-Cd11a Antibodies
  • Method For Detecting The Presence Of P-Selectin
  • Methods And Means For The Production Of Ig-Like Molecules
  • Monoclonal Antibodies That Bind B7h6 And Uses Thereof
  • Humanized Anti-Beta7 Antagonists And Uses Therefor
  • Bgl7 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Polynucleotides Encoding Anti-Ganglioside Antibodies
  • Anti-Ngf Antibodies And Methods Using Same
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Engineered Anti-Il-23p19 Antibodies
  • Humanized Anti-Prostate Stem Cell Antigen Monoclonal Antibody
  • Protein Kinase Ck2 Gene Mutations, Amplifications And Polymorphisms In Human Cancers And Methods Of Use
  • Dipeptide Analogs For Treating Conditions Associated With Amyloid Fibril Formation
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Psca: Prostate Stem Cell Antigen And Uses Thereof In Pancreatic Cancer
  • Methods Of Using Il-6r Antibodies To Block Or Reduce Binding Of Il-6 To Il-6r
  • Binding Domain-Immunoglobulin Fusion Proteins
  • Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections
  • Antibodies To Matrix Metalloproteinase 9
  • Synthetic Peptide Constructs For The Diagnosis And Treatment Of Periodontitis Associated With Porphyromonas Gingivalis
  • Cytotoxic Peptides And Antibody Drug Conjugates Thereof
  • Method For Generating Active Antibodies Against A Resistance Antigen, Antibodies Obtained By Said Method And Their Uses
  • Prevention, Treatment And Diagnosis Of P. Gingivalis Infection
  • Protein Formulation
  • Human Cdr-Grafted Antibody And Antibody Fragment Thereof
  • Engineered Anti-Il-23p19 Antibodies
  • Microporous Materials, Methods Of Making, Using, And Articles Thereof
  • Antibodies Directed Toward The Hiv-1 Gp120 Cd4 Binding Site With Increased Potency And Breadth
  • Regulation Of Endogenous Gene Expression In Cells Using Zinc Finger Proteins
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Human M2e Peptide Immunogens
  • Anti-Gpr49 Monoclonal Antibodies
  • Anti-Dll3 Antibody Drug Conjugates And Methods Of Use
  • Method For Tapping The Immunological Repertoire
  • Amyloid Precursor-Like Protein And Uses Thereof
  • Treatment For Insulin Dependent Diabetes
  • Methods For Expressing And Recovering Human Monoclonal Antibodies To Ctla-4
  • Methods Of Treating Cancer Using Pd-1 Axis Binding Antagonists And Mek Inhibitors
  • Endosialin-Binding Antibody
  • Automatic Calibration Systems And Methods Of Use
  • Antibodies To The Human Prolactin Receptor
  • Il-1 Binding Proteins
  • Method For Producing Polymers Having A Preselected Activity
  • Methods For Assessing Responsiveness Of B-Cell Lymphoma To Treatment With Anti-Cd40 Antibodies
  • Therapeutic Compositions Comprising Anti-Ige Antibodies And Immunosuppressive Agent
  • Methods Of Producing Immunoglobulins, Vectors And Transformed Host Cells For Use Therein
  • Method For The Treatment Of Inflammatory Disorders
  • Anti-Cd26 Antibodies And Methods Of Use Thereof
  • Humanized Antibody
  • Anti-Her2 Antibody Variants
  • Members Of The Fc Receptor Homolog Gene Family (Fcrh1-3, 6), Related Reagents, And Uses Thereof
  • Enhancement Of Antibody-Mediated Immune Responses
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Method Of Treating Type 1 Diabetes By Administering Nkp46 Polypeptide
  • Methods And Compositions For Screening And Detecting Biomarkers
  • Methods And Compositions For Inhibiting Cd32b Expressing Cells
  • Kits Containing Dll3 Antibody Drug Conjugates
  • Methods Of Targeting Multiple Cytokines
  • Genetically Modified Human Natural Killer Cell Lines
  • Methods For Treating Pain By Administering A Nerve Growth Factor Antagonist And An Nsaid And Compositions Containing The Same
  • Compositions And Methods For Treatment Of Cancer
  • Antibody Specificity Transfer Using Minimal Essential Binding Determinants
  • Nucleic Acid Molecules Encoding Minimally Immunogenic Variants Of Sdr-Grafted Humanized Antibody Cc49
  • Method For Using Boc/Cdo To Modulate Hedgehog Signaling
  • Monoclonal Antibody To A Human Mdr1 Multidrug Resistance Gene Product, And Uses
  • Antigen-Presenting Complex-Binding Compositions And Uses Thereof
  • Humanized Anti-Beta7 Antagonists And Uses Therefor
  • Raag10 Cell Surface Target And A Family Of Antibodies Recognizing That Target
  • A Method Of Rational Antibody Design
  • Methods Of Delivering Dll3 Antibody Drug Conjugates
  • Antibodies Against Platelet-Derived Growth Factor (Pdgf)
  • Non-Antagonistic Antibodies Directed Against The Alpha Chain Of The Il7 Receptor Extracellular Domain And Use Thereof In Cancer Treatment
  • Minimally Immunogenic Variants Of Sdr-Grafted Humanized Antibody Cc49 And Their Use
  • Compositions And Methods For The Treatment And Prevention Of Hyperproliferative Diseases
  • Artificial Antibody Polypeptides
  • Peptide Nanostructures And Methods Of Generating And Using The Same
  • Methods For Treating Obesity Using Fibroblast Growth Factor-Like Polypeptides
  • Antibodies To Masp-2
  • Dna Encoding Il-2 Fusion Proteins With Modulated Selectivity
  • Binding Proteins For Recognition Of Dna
  • Antibodies For Inhibiting Blood Coagulation And Methods Of Use Thereof
  • Apo-2 Receptor Polypeptides
  • Egvi Endoglucanase And Nucleic Acids Encoding The Same
  • Relating To Binding Proteins For Recognition Of Dna
  • Compositions And Methods For Binding Lysophosphatidic Acid
  • Methods And Compositions For Prostate Cancer Metastasis
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Biological Materials And Uses Thereof
  • Trem2 Cleavage Modulators And Uses Thereof
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Anti-Kidney Associated Antigen 1 (Kaag1) Antibodies
  • Methods Of Producing Immunoglobulins, Vectors And Transformed Host Cells For Use Therein
  • Protein Formulation
  • Members Of The Fc Receptor Homolog Gene Family (Fcrh1-3, 6), Related Reagents, And Uses Thereof
  • Methods For Expressing And Recovering Human Monoclonal Antibodies To Ctla-4
  • Antibodies Directed Toward The Hiv-1 Gp120 Cd4 Binding Site With Increased Potency And Breadth
  • Regulation Of Endogenous Gene Expression In Cells Using Zinc Finger Proteins
  • Anti-Gpr49 Monoclonal Antibodies
  • Automatic Calibration Systems And Methods Of Use
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Anti-Dll3 Antibody Drug Conjugates And Methods Of Use
  • Methods Of Treating Cancer Using Pd-1 Axis Binding Antagonists And Mek Inhibitors
  • Endosialin-Binding Antibody
  • Microporous Materials, Methods Of Making, Using, And Articles Thereof
  • Engineered Anti-Il-23p19 Antibodies
  • Human Cdr-Grafted Antibody And Antibody Fragment Thereof
  • Methods For Assessing Responsiveness Of B-Cell Lymphoma To Treatment With Anti-Cd40 Antibodies
  • Human Immunoglobulines Produced By Recombinant Dna Techniques
  • Enzymatic Conjugation Of Antibodies
  • Antibodies That Bind Il-4 And/Or Il-13 And Their Uses
  • Methods And Systems For Transforming Luminal Images
  • Polynucleotides Encoding Anti-Gd2 Antibodies
  • Antigen-Presenting Complex-Binding Compositions And Uses Thereof
  • Humanized Anti-Beta7 Antagonists And Uses Therefor
  • Raag10 Cell Surface Target And A Family Of Antibodies Recognizing That Target
  • Methods Of Targeting Multiple Cytokines
  • Minimally Immunogenic Variants Of Sdr-Grafted Humanized Antibody Cc49 And Their Use
  • Hybrid Antibodies
  • Enhancement Of Antibody-Mediated Immune Responses
  • Antibodies To The Human Prolactin Receptor
  • Uses Of Fgf21 Polypeptides Comprising Two Or More Mutations
  • Antibody Variants With Enhanced Complement Activity
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Methods Of Modulating Immune Function
  • Reconstituted Polypeptides
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Compositions And Methods For Production Of Immunoglobulins
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Hcv Ns3 Recombinant Antigens And Mutants Thereof For Improved Antibody Detection
  • Chimeric Ospa Genes, Proteins And Methods Of Use Thereof
  • Iconic Communication
  • Anti-Cmet Antibody
  • Therapeutic Compositions For The Treatment Of Dry Eye Disease
  • Method For Using Boc/Cdo To Modulate Hedgehog Signaling
  • Bh3 Peptides And Method Of Use Thereof
  • Antibodies With Immune Effector Activity And That Internalize In Endosialin-Positive Cells
  • Anti-Mesothelin Antibodies
  • Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes
  • Anti-Cea Antibodies
  • Amyloid Precursor-Like Protein And Uses Thereof
  • Treatment For Insulin Dependent Diabetes
  • Method For Tapping The Immunological Repertoire
  • Therapeutic Compositions Comprising Anti-Ige Antibodies And Immunosuppressive Agent
  • Method For The Treatment Of Inflammatory Disorders
  • Anti-Cd26 Antibodies And Methods Of Use Thereof
  • Humanized Antibody
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Method For Identifying Active Domains And Amino Acid Residues In Polypeptides And Hormone Variants
  • Apo-2-Receptor
  • Methods For Identifying Inhibitors Of Neuronal Degeneration
  • Compositions And Methods For Treatment Of Cancer
  • Cell Migration Assay
  • Matrix Metalloproteinase Polypeptide
  • Anti-Dll3 Antibody Drug Conjugates For Treating Cancer
  • Methods For Detecting Prostate Stem Cell Antigen Protein
  • Humanized Antibodies And Methods For Making Them
  • Anti-Ige Antibodies And Methods Of Improving Polypeptides
  • Apo-2 Ligand
  • Antibodies Against A Host Cell Antigen Complex For Pre And Post Exposure Protection From Infection By Hiv
  • Luminescent Chimeric Proteins
  • Method For Identifying Active Domains And Amino Acid Residues In Polypeptides And Hormone Variants
  • Modular Assembly Of Antibody Genes, Antibodies Prepared Thereby And Use
  • Antibodies Against E-Selectin
  • Nucleic Acids Encoding Interleukin-5 Specific Recombinant Antibodies
  • Human Fibroblast Diffusable Factors
  • Anti-Dota Antibody
  • Antithrombotic Agent And Humanized Anti-Von Willebrand Factor Monoclonal Antibody
  • Cytokine Receptors And Nucleic Acids Encoding The Same
  • Treatment For Asthma With Vla-4 Blocking Agents
  • Modified Antibody Variable Domains
  • Totally Synthetic Affinity Reagents
  • Serine Threonine Kinase Receptor, Alk-7
  • Hepatocyte Growth Factor Receptor Antagonist Antibodies And Uses Thereof
  • Chimeric Antibody With Specificity To Human B Cell Surface Antigen
  • Modified Antibody Variable Domains
  • Immunotoxins Comprising Ribosome-Inactivating Proteins
  • Apo-2 Ligand
  • Variants Of Humanized Anti Carcinoma Monoclonal Antibody Cc49
  • Cdna Encoding A Gene Bog (B5t Over-Expressed Gene) And Its Protein Product
  • Method For Producing Polymers Having A Preselected Activity
  • Flt4 (Vegfr-3) As A Target For Tumor Imaging And Anti-Tumor Therapy
  • Humanized Immunoglobulins
  • Hcv Core Lipid Binding Domain Monoclonal Antibodies
  • Monoclonal Antibody Binding To Mt4-Mmp Catalytic Domain
  • Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus
  • Tes7 And Antibodies That Bind Thereto
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Biosynthetic Antibody Binding Sites
  • Method For Making Humanized Antibodies
  • Anti Cxcr4 Antibodies And Their Use For The Treatment Of Cancer
  • Method For The Treatment Of Inflammatory Disorders
  • Drosophila G Protein Coupled Receptors, Nucleic Acids, And Methods Related To The Same
  • Nucleic Acid Encoding Anti-Ige Antibodies
  • Antibodies To Opgl
  • Drosophila G Protein Coupled Receptors, Nucleic Acids, And Methods Related To The Same
  • Cd16a Binding Proteins And Use For The Treatment Of Immune Disorders
  • Il-1 Binding Proteins
  • Methods For Treating Pain By Administering A Nerve Growth Factor Antagonist And An Nsaid And Compositions Containing The Same
  • Method For Producing Polymers Having A Preselected Activity
  • Iconic Communication
  • Humanized Anti-Factor D Antibodies And Uses Thereof
  • Binding Proteins That Bind To Human Fgfr1c, Human Β-Klotho And Both Human Fgfr1c And Human Β-Klotho
  • Compositions And Methods Using Same For Treating Amyloid-Associated Diseases
  • Humanized Cdr-Grafted Anti-Icam-1 Antibodies, Methods Of Preparation And Usage Thereof
  • Improved Humanized Immunoglobulins
  • Human M2e Peptide Immunogens
  • Prevention, Treatment And Diagnosis Of P. Gingivalis Infection
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Engineered Anti-Il-23p19 Antibodies
  • Humanized Anti-Prostate Stem Cell Antigen Monoclonal Antibody
  • Protein Kinase Ck2 Gene Mutations, Amplifications And Polymorphisms In Human Cancers And Methods Of Use
  • Dipeptide Analogs For Treating Conditions Associated With Amyloid Fibril Formation
  • Psca: Prostate Stem Cell Antigen And Uses Thereof In Pancreatic Cancer
  • Anti-Her2 Antibody Variants
  • Binding Domain-Immunoglobulin Fusion Proteins
  • Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections
  • Cytotoxic Peptides And Antibody Drug Conjugates Thereof
  • Method For Generating Active Antibodies Against A Resistance Antigen, Antibodies Obtained By Said Method And Their Uses
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Anti-Glycoprotein Vi Scfv Fragment For Treatment Of Thrombosis
  • Anti-Glycoprotein Vi Scfv Fragment For Treatment Of Thrombosis
  • Genetically Modified Human Natural Killer Cell Lines
  • Monoclonal Antibody To A Human Mdr1 Multidrug Resistance Gene Product, And Uses
  • Compositions And Methods For Treatment Of Cancer
  • Antibody Specificity Transfer Using Minimal Essential Binding Determinants
  • Nucleic Acid Molecules Encoding Minimally Immunogenic Variants Of Sdr-Grafted Humanized Antibody Cc49
  • Antibodies Against Platelet-Derived Growth Factor (Pdgf)
  • Non-Antagonistic Antibodies Directed Against The Alpha Chain Of The Il7 Receptor Extracellular Domain And Use Thereof In Cancer Treatment
  • Methods And Compositions For Inhibiting Cd32b Expressing Cells
  • Kits Containing Dll3 Antibody Drug Conjugates
  • Methods And Compositions For Screening And Detecting Biomarkers
  • Method Of Treating Type 1 Diabetes By Administering Nkp46 Polypeptide
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Antibodies To Matrix Metalloproteinase 9
  • Synthetic Peptide Constructs For The Diagnosis And Treatment Of Periodontitis Associated With Porphyromonas Gingivalis
  • Methods Of Using Il-6r Antibodies To Block Or Reduce Binding Of Il-6 To Il-6r
  • Method For Making Heteromultimeric Molecules
  • Nucleotide And Amino Acid Sequences Encoding An Exported Protein 1 Derived From Plasmodium Vivax And Uses Thereof
  • A Method Of Rational Antibody Design
  • Methods Of Delivering Dll3 Antibody Drug Conjugates
  • Anti-Htra1 Antibodies And Methods Of Use
  • Reactive Labelling Compounds And Uses Thereof
  • Ferroportin Antibodies And Methods Of Use
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Compositions And Methods For Diagnosing And Treating Cancer
  • Reducing The Immunogenicity Of Fusion Proteins
  • Methods Of Treatment Using Adm Antibodies
  • Microporous Materials, Methods Of Making, Using, And Articles Thereof
  • Polynucleotides Encoding Humanized Anti-Factor D Antibodies
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Anti-Inflammatory Dab
  • Combination Therapy With Anti-Cd74 And Anti-Cd20 Antibodies Provides Enhanced Toxicity To B-Cell Diseases
  • Delivering Functional Nucleic Acids To Mammalian Cells Via Bacterially-Derived, Intact Minicells
  • Fgf 21 Polypeptides Comprising Two Or More Mutations And Uses Thereof
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Anti-Vegf Antibodies
  • Spliceostatin Analogs And Methods For Their Preparation
  • Targeted Cryptosporidium Biocides
  • Anti-Glycoprotein Vi Scfv Fragment For Treatment Of Thrombosis
  • Humanized Anti-Beta7 Antagonists And Uses Therefor
  • Humanized Anti-Claudin-1 Antibodies And Uses Thereof
  • Anti-Human P-Cadherin (Cdh3) Recombinant Antibody
  • Anti-Dll3 Antibody Drug Conjugates For Treating Cancer
  • Antibodies To Apo-2 Receptor Polypeptides
  • Fully Human Antibodies Against Human 4-1bb
  • Antibodies To Vla-1
  • Methods And Compositions For Inhibiting Cd32b Expressing Cells
  • Anti Ceacam1 Antibodies And Methods Of Using Same
  • Monoclonal Antibodies That Specifically Block Biological Activity Of A Tumor Antigen
  • Antibodies Against E-Selectin
  • Anti-Clusterin Antibodies And Antigen Binding Fragments And Their Use To Reduce Tumor Volume
  • Compositions And Methods For Treating Cellular Response To Injury And Other Proliferating Cell Disorders Regulated By Hyaladherin And Hyaluronans
  • Anti-Igf-Ir Antibodies And Uses Thereof
  • Antibodies With Immune Effector Activity And That Internalize In Endosialin-Positive Cells
  • Vegf Binding Antibodies
  • Framework Mutated Antibodies And Their Preparation
  • Engineered Anti-Il-23p19 Antibodies
  • Compositions And Methods For Treating Pigmentary Conditions And Melanoma
  • Stem Cell Factor Inhibitor
  • Artificial Antibody Polypeptides
  • Method For Making Heteromultimeric Molecules
  • Polypeptides And Use Thereof
  • Method Of Overcoming Therapeutic Limitations Of Nonuniform Distribution Of Radiopharmaceuticals And Chemotherapy Drugs
  • Antibodies To Vla-1
  • Nad Biosynthesis And Precursors For The Treatment And Prevention Of Cancer And Proliferation
  • Bispecific Antibodies Comprising A Disulfide Stabilized-Fv Fragment
  • Modified Immunoglobulin Molecules That Specifically Bind Human Vegf And Dll4
  • Use Of Dr6 And P75 Antagonists To Promote Survival Of Cells Of The Nervous System
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Il-1 Binding Proteins
  • Il-1 Binding Proteins
  • Methods And Compositions For The Treatment Of Proliferative And Pathogenic Diseases
  • Decreasing Lactate Level And Increasing Polypeptide Production By Downregulating The Expression Of Lactate Dehydrogenase And Pyruvate Dehydrogenase Kinase
  • Bispecific Molecules That Are Immunoreactive With Immune Effector Cells Of A Companion Animal That Express An Activating Receptor And Cells That Express B7-H3 And Uses Thereof
  • Compositions Comprising Polyglutamic Acid Nanoparticles And Cd40 Agonists
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Use
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or Anti-Adm Non-Ig Scaffold For Reducing The Risk Of Mortality In A Patient Having A Chronic Or Acute Disease Or Acute Condition
  • Cytotoxic Peptides And Antibody Drug Conjugates Thereof
  • Assay For Measurement Of Antibodies Binding To A Therapeutic Monoclonal Antibody
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Multiple Signaling Pathways Induced By Hexvalent, Monospecific And Bispecific Antibodies For Enhanced Toxicity To B-Cell Lymphomas And Other Diseases
  • Human Anti-Ifn-Γ Neutralizing Antibodies As Selective Ifn-Γ Pathway Inhibitors
  • Novel Anti-Fcyriib Igg-Type Antibody
  • M-Csf-Specific Monoclonal Antibody And Uses Thereof
  • Bacterially Derived Intact Minicells That Encompass Plasmid Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Fusion Antibodies For Hiv Therapy
  • Porphyromonas Gingivalis Polypeptides And Nucleotides
  • Anti-Mesothelin Antibodies
  • Antibodies Specific For Tgf-Beta And Methods For Treating Thereof
  • Neuritogenic Peptides
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Psca: Prostate Stem Cell Antigen And Uses Thereof
  • Highly Concentrated Stabilized Igm Solution
  • B7-H3l Cell Surface Antigen And Antibodies That Bind Thereto
  • Humanized Anti-Beta7 Antagonists And Uses Therefor
  • Method Of Producing A Pigmented Composite Microporous Material
  • Anti-Mesothelin Antibodies
  • Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus
  • Humanized Anti-Tag 72 Cc49 For Diagnosis And Therapy Of Human Tumors
  • Cd16a Binding Proteins And Use For The Treatment Of Immune Disorders
  • Transgenic Animals For Producing Specific Isotypes Of Human Antibodies Via Non-Cognate Switch Regions
  • Antibodies And Pharmaceutical Compositions Containing Same Useful For Inhibiting Activity Of Metalloproteins
  • Enhancing The Circulating Half-Life Of Antibody-Based Fusion Proteins
  • Hcv Antigen-Antibody Combination Assay And Methods And Compositions For Use Therein
  • Pd-1 Specific Antibodies And Uses Thereof
  • Methods And Materials For Detecting C9orf72 Hexanucleotide Repeat Expansion Positive Frontotemporal Lobar Degeneration Or C9orf72 Hexanucleotide Repeat Expansion Positive Amyotrophic Lateral Sclerosis
  • Heterodimeric Proteins
  • Spliceostatin Analogs And Methods For Their Preparation
  • Fgf21 Mutants And Uses Thereof
  • Immuno-Pet Imaging Of Antibodies And Immunoconjugates And Uses Therefor
  • Antibodies Directed To Angiopoietin-1 And Angiopoietin-2 And Uses Thereof
  • Neutralizing Monoclonal Antibodies To Respiratory Syncytial Virus
  • Bgl7 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Antibodies Inhibiting C-Met Dimerization And Uses Thereof
  • Fusion Proteins For Modulating Regulatory And Effector T Cells
  • Multianalyte Assay
  • Anti-Interferon-Α Antibodies
  • Beta Secretase Polypeptides
  • Heterodimeric Fusion Proteins Useful For Targeted Immune Therapy And General Immune Stimulation
  • Relating To Binding Proteins For Recognition Of Dna
  • Nucleic Acids Encoding Antibodies To Matrix Metalloproteinase 9
  • Antibodies Against The Rgm A Protein And Uses Thereof
  • Antibodies That Bind To Repulsive Guidance Molecule A (Rgma)
  • Dock-And-Lock (Dnl) Complexes For Therapeutic And Diagnostic Use
  • Antigen Binding Molecules With Increased Fc Receptor Binding Affinity And Effector Function
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Humanized Anti-Factor D Antibodies
  • Hybrid Antibodies
  • Fgf-21 Mutants Comprising Polyethylene Glycol And Uses Thereof
  • Hybrid Antibodies
  • Method For The Generation Of Proliferating And Differentiating B Cell Lines
  • Anti-Cancer Antibodies With Reduced Complement Fixation
  • Methods For Blocking Or Reducing Binding Of Interleukin-6 To Interleukin-6 Receptor
  • Microarrays And Uses Therefor
  • Peptides Directed For Diagnosis And Treatment Of Amyloid-Associated Diseases
  • Monoclonal Antibody Capable Of Binding Integrin Alpha 10 Beta 1
  • Anti-Ige Antibodies And Method Of Improving Polypeptides
  • Human Growth Hormone Variants Having Enhanced Affinity For Human Growth Hormone Receptor At Site 1
  • Antibodies To Fas-L For Treatment Of Hepatitis
  • Modified Antibodies
  • Coiled Coil And/Or Tether Containing Protein Complexes And Uses Thereof
  • Variants Of Human Prolactin And Human Placeatal Lactogen
  • Method Of Enhancing Proliferation Or Differentiation Of Hematopoietic Stem Cells Using Wnt Polypeptides
  • Epitope Which Binds To Monoclonal Antibody
  • Totally Synthetic Affinity Reagents
  • Methods Of Inducing Or Enhancing An Immune Response In A Subject Having Cancer By Administering Gitr Antibodies
  • Recognition Tags For Tgase-Mediated Conjugation
  • Methods Of Improving Vaccine Immunogenicity
  • Antibodies That Specifcally Bind Sost And Wise Peptides
  • Thrombin/Plasmin-Regulated Antibodies That Bind Tfpi
  • Anti-Ox40 Antibodies And Methods Of Use
  • Antibody Formulations
  • Dendritic Cell Marker And Uses Thereof
  • Signal Biomarkers
  • Polypeptide Linkers For Production Of Biosynthetic Proteins
  • Therapeutic Targets In Cancer
  • Methods And Compositions For Rapid Light-Activated Isolation And Detection Of Analytes
  • Human Monoclonal Antibodies Against Cd25
  • Methods For Decreasing Immune Response And Treating Immune Conditions
  • Anti-Ox40l Antibodies
  • Kid31 And Antibodies That Bind Thereto
  • Humanized Anti-Beta7 Antagonists And Uses Therefor
  • Gamma-1 And Gamma-3 Anti-Human Cd23 Monoclonal Antibodies And Use Thereof As Therapeutics
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Methods Of Reducing Trail-Induced Apoptosis By Trail Isoforms
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Anti-Factor B Antibodies And Their Uses
  • Antibodies To Vla-1
  • Anti-Cd26 Antibodies And Methods Of Use Thereof
  • Antibodies Directed To Angiopoietin-1 And Angiopoietin-2 And Uses Thereof
  • Method Of Treating Breast Cancer Using Anti-Her2 Antibody Variants
  • Nucleotide And Amino Acid Sequences Encoding An Exported Protein 1 Derived From Plasmodium Vivax And Uses Thereof
  • Methods For Inhibiting The Binding Of Endosialin To Ligands
  • Engineered Anti-Il-23 Antibodies
  • Dual Expression Vector System For Antibody Expression In Bacterial And Mammalian Cells
  • Humanized Anti-Amyloid Antibody
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Polynucleotides Encoding Fully Human Antibodies Against Human 4-1bb
  • Peptide Nanostructure-Coated Electrodes
  • Peptide Nanostructures Containing End-Capping Modified Peptides And Methods Of Generating And Using The Same
  • Method Of Inhibiting Factor B-Mediated Complement Activation
  • Trypanosoma Cruzi Proteome Compositions And Methods
  • Transgenic Mammals Having Human Ig Loci Including Plural Vh And Vk Regions And Antibodies Produced Therefrom
  • Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells
  • Apo-2 Receptor Polynucleotides
  • Hgf Beta Chain Variants
  • Variant Fc Regions
  • Antibodies To Gm-Csf
  • Cbh1 Homologs And Variant Cbh1 Cellulases
  • Nucleotide And Amino Acid Sequences Encoding An Exported Protein 1 Derived From Plasmodium Vivax And Uses Thereof
  • Methods Of Ex Vivo Hematopoietic Stem Cell Expansion By Co-Culture With Mesenchymal Cells
  • Methods Of Screening For Agonists And Antagonists Of Patched-2
  • Anti-Vegf Antibodies
  • Method And Apparatus To Identify Vulnerable Plaques With Thermal Wave Imaging Of Heated Nanoparticles
  • Artificial Antibody Polypeptides
  • Anti-Ngf Antibodies And Methods Using Same
  • Antibodies To Receptor Of Advanced Glycation End Products (Rage) And Uses Thereof
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Monoclonal Antibody Capable Of Binding Integrin Alpha 10 Beta 1
  • Human-Murine Chimeric Antibodies Against Respiratory Syncytial Virus
  • Cdr-Repaired Antibodies
  • Ephb3-Specific Antibody And Uses Thereof
  • Methods Of Generating Libraries And Uses Thereof
  • Chimeric Ospa Genes, Proteins, And Methods Of Use Thereof
  • Chimeric Ospa Genes, Proteins, And Methods Of Use Thereof
  • Nucleic Acids Encoding B7rp1
  • Dengue-Virus Serotype Neutralizing Antibodies
  • Compositions And Methods For Modulating Ghrelin-Mediated Conditions
  • High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or Anti-Adm Non-Ig Scaffold For Reducing The Risk Of Mortality In A Patient Having A Chronic Or Acute Disease Or Acute Condition
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or An Anti-Adm Non-Ig Scaffold For Use In Therapy
  • Carrier Molecules
  • Method Of Including Apoptosis By Reducing The Level Of Thiamin
  • Humanized Antibodies
  • Modulation Of Endogenous Gene Expression In Cells
  • Apo-2 Ligand
  • Treatment For Inflammatory Bowel Disease With A Fibronectin Polypeptide
  • Humanised Antibodies
  • Growth Hormone Variants
  • Human Monoclonal Antibody Specifically Binding To Surface Antigen Of Cancer Cell Membrane
  • Patched-2
  • Nucleic Acid Encoding Patched-2
  • Methods For Treating Cancer Using Psca Antibodies And Fragments Thereof
  • Methods Of Determining Cellular Chemosensitivity
  • Therapeutic Use Of Anti-Cd22 Antibodies For Inducing Trogocytosis
  • Method For Making Monoclonal Antibodies And Cross-Reactive Antibodies Obtainable By The Method
  • Fusion Proteins And Polynucleotides Encoding Gelonin Sequences
  • Biofilm Treatment
  • Bgl6 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Therapeutic Use Of Anti-Cd22 Antibodies For Inducing Trogocytosis
  • Ultrapurified Dsba And Dsbc And Methods Of Making And Using The Same
  • Antibodies That Specifically Bind Pms2
  • Pentapeptide Compounds And Uses Related Thereto
  • Polynucleotides Encoding Antibodies Directed Against Amyloid-Beta Peptide
  • Covalent Diabodies And Uses Thereof
  • Cancer Treatments Including Administering Il-2 Fusion Proteins With Modulated Selectivity
  • Recombinant Tumor Specific Antibody And Use Thereof
  • Monoclonal Antibody Capable Of Binding Integrin Alpha 10 Beta 1
  • Hxhv Virus, Nucleic Material, Peptide Material And Uses
  • Nanoparticles Containing Polymeric Nucleic Acid Homologs
  • Antibodies Against Kidney Associated Antigen 1 And Antigen Binding Fragments Thereof
  • Antibodies To Receptor Of Advanced Glycation End Products (Rage) And Uses Thereof
  • Methods Of Inhibiting Solid Tumor Growth By Administering Gpr49 Antibodies
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Fgf21 Mutants Comprising A Mutation At Position 98, 171 And/Or 180
  • Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
  • Methods For Inhibiting The Binding Of Endosialin To Ligands
  • Methods For Treating Progressive Multiple Sclerosis
  • Dipeptide Analogs For Treating Conditions Associated With Amyloid Fibril Formation
  • Human Antigen Binding Proteins That Bind Β-Klotho, Fgf Receptors And Complexes Thereof
  • Substituted Pyrazines As Cadherin-11 Inhibitors
  • Genetically Modified Human Natural Killer Cell Lines
  • Antibodies For The Treatment Of Hiv
  • Method For Treating Cancer Using An Antibody That Inhibits Notch4 Signaling
  • Cell Migration Assay
  • Granulocyte-Binding Antibody Constructs, Their Preparation And Use
  • Humanized Antibodies Reactive With Gpiib/Iiia
  • Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf) Neutralizing Antibodies
  • Anti-Dll3 Antibody Drug Conjugates And Methods Of Use
  • Methods Of Reducing Level Of One Or More Impurities In A Sample During Protein Purification
  • Immunoglobulins And Variants Directed Against Pathogenic Microbes
  • System And Method For Oct Depth Calibration
  • Fgf Mutants With Reduced Proteolysis And Aggregation
  • Antibodies Reactive With B7-H3 And Uses Thereof
  • B7-H3l Cell Surface Antigen And Antibodies That Bind Thereto
  • Humanized Antibodies
  • Methods Of Treating Thrombotic Diseases With Von Willebrand Factor Specific Antibodies
  • Increasing Antibody Affinity By Altering Glycosylation Of Immunoglobulin Variable Region
  • Method For Producing Polymers Having A Preselected Activity
  • Method For In Vivo Selection Of Ligand-Binding Proteins
  • Variant Galactose Oxidase, Nucleic Acid Encoding Same, And Methods Of Using Same
  • Production Of Tnfr-Ig
  • Enhancing The Circulating Half-Life Of Antibody-Based Fusion Proteins
  • Humanized Antibodies Against Human 4-1bb
  • Pseudomonas Exotoxin A With Less Immunogenic T Cell And/Or B Cell Epitopes
  • Bacterially Derived, Intact Minicells Encompassing Regulatory Rna
  • Linked Peptides Fluorogenic Biosensors
  • Influenza Virus Antibody Compositions
  • Anti-Bv8 Antibodies And Uses Thereof
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Regulation Of Endogenous Gene Expression In Cells Using Zinc Finger Proteins
  • Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells
  • Ungulates With Genetically Modified Immune Systems
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Monoclonal Antibodies To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9)
  • Anti-Cmet Antibody
  • Targeted Delivery Of Drugs, Therapeutic Nucleic Acids And Functional Nucleic Acids To Mammalian Cells Via Intact Killed Bacterial Cells
  • Combination Therapies Employing Gitr Binding Molecules
  • Anti-Cxcr4 Antibodies And Antibody-Drug Conjugates
  • Compositions And Methods Useful For Stabilizing Protein-Containing Formulations
  • Il-17 Binding Proteins
  • Therapeutic Use Of Anti-Cd22 Antibodies For Inducing Trogocytosis
  • Method Of Determining Virus Removal From A Sample Containing A Target Protein Using Activated Carbon
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Kits Containing Dll3 Antibody Drug Conjugates
  • Antibodies Against The Rgm A Protein And Uses Thereof
  • Methods Of Culturing And Expanding Mesenchymal Stem Cells
  • Methods And Compositions For Modulating Hepsin Activation Of Macrophage-Stimulating Protein
  • Anti-Cmet Antibody
  • Therapeutic Dll4 Binding Proteins
  • Anti-Dll3 Antibody Drug Conjugates
  • Peptides And Methods Using Same For Diagnosis And Treatment Of Amyloid-Associated Disease
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Il-17 Binding Proteins
  • Anti-Notch3 Antibodies And Antibody-Drug Conjugates
  • Antigen Binding Protein And Its Use As Addressing Product For The Treatment Of Cancer
  • Anti-Vegf Antibodies
  • Compositions And Methods For The Therapy And Diagnosis Of Influenza
  • Anti-Cmet Antibody
  • Human Growth Hormone Variants
  • Antibody-Sn-38 Immunoconjugates With A Cl2a Linker
  • Anti-Glucosaminidase Passive Immunization For Staphylococcus Aureus Infections
  • Anti Human Interleukin-1 Receptor Accessory Protein (Il1 Rap) Antibodies And Uses Thereof
  • Cadherin-11 Inhibitors And Methods Of Use Thereof
  • Cytolethal Distending Toxin Subunit B Conjugated Or Fused To Bacillus Anthracis Toxin Lethal Factor
  • Highly Active Agonistic Cd4 Binding Site Anti-Hiv Antibodies (Haads) Comprising Modified Cdrh2 Regions That Improve Contact With Gp120
  • Peptide Inhibitors Of Bace1
  • Prevention, Treatment And Diagnosis Of P. Gingivalis Infection
  • High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
  • Ror1-Binding Molecules, And Methods Of Use Thereof
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Methods And Compositions For Assessing Responsiveness Of B-Cell Lymphoma To Treatment With Anti-Cd40 Antibodies
  • Antibodies To Receptor For Advanced Glycation End Products (Rage) And Uses Thereof
  • Multimeric Proteins And Methods Of Making And Using Same
  • Bgl3 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Methods For Inducing Or Enhancing An Immune Response By Administering Agonistic Gitr-Binding Antibodies
  • Hepatocyte Growth Factor Receptor Antagonists And Uses Thereof
  • Vertebrate Smoothened Proteins
  • Human Inkt Cell Activation Using Glycolipids
  • Gitr Antigen Binding Proteins And Methods Of Use Thereof
  • High Throughput Generation And Affinity Maturation Of Humanized Antibody
  • Modified Pseudomonas Exotoxin A
  • Humanized Anti-Tag 72 Cc49 For Diagnosis And Therapy Of Human Tumors
  • Treatment With Anti-Alpha2 Integrin Antibodies
  • System For Antibody Expression And Assembly
  • Anti-Gd2 Antibodies
  • Antigen Binding Protein And Its Use As Addressing Product For The Treatment Of Cancer
  • Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator Of Tumor Aggressiveness And Potential Therapeutic Target
  • Dock-And-Lock (Dnl) Complexes For Therapeutic And Diagnostic Use
  • Methods For Treating Conditions Associated With Masp-2 Dependent Complement Activation
  • Antigen Binding Proteins
  • Locating Intravascular Images
  • Intravascular Forward Imaging Device
  • Human Il-23 Antigen Binding Proteins
  • Cd3-Binding Molecules Capable Of Binding To Human And Non-Human Cd3
  • Anti-Interferon-Α Antibodies
  • Anti-C-Met Antibody
  • Antibodies To Lymphotoxin-Α
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Immunoglobulin Variants And Uses Thereof
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or An Anti-Adm Non-Ig Scaffold For Use In Therapy
  • Biomarkers
  • Human Monoclonal Antibodies To Ctla-4
  • Method Of Inducing Apoptosis By Reducing The Level Of Thiamin
  • Anti-Dll4 Antibodies And Methods Using Same
  • Methods For Stabilizing Protein Solutions
  • Labeled Peptides, Proteins And Antibodies And Processes And Intermediates Useful For Their Preparation
  • Anti-Ganglioside Antibodies And Compositions
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or Anti-Adm Non-Ig Scaffold For Reducing The Risk Of Mortality In A Patient Having A Chronic Or Acute Disease Or Acute Condition
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or Anti-Adm Non-Ig Scaffold For Use In Therapy Of An Acute Disease Or Acute Condition Of A Patient For Stabilizing The Circulation
  • Antibodies To Lymphotoxin-Α
  • Biomarkers
  • Anti-Interferon-Α Antibodies
  • Pseudomonas Exotoxin A With Reduced Immunogenicity
  • Cd3-Binding Molecules Capable Of Binding To Human And Non-Human Cd3
  • Synthetic Immunoglobulin Domains With Binding Properties Engineered In Regions Of The Molecule Different From The Complementarity Determining Regions
  • Guidewire Artifact Removal In Images
  • Antibodies To Plasminogen Activator Inhibitor-1 (Pai-1) And Uses Thereof
  • Humanized Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Costimulatory B7-H1 In Renal Cell Carcinoma Patients: Indicator Of Tumor Aggressiveness And Potential Therapeutic Target
  • Dock-And-Lock (Dnl) Complexes For Therapeutic And Diagnostic Use
  • Antigen Binding Proteins
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or An Anti-Adm Non-Ig Scaffold For Use In Therapy
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or Anti-Adm Non-Ig Scaffold For Reducing The Risk Of Mortality In A Patient Having A Chronic Or Acute Disease Or Acute Condition
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment Or Anti-Adm Non-Ig Scaffold For Use In Therapy Of An Acute Disease Or Acute Condition Of A Patient For Stabilizing The Circulation
  • Monoclonal Antibodies To Growth And Differentiation Factor 15 (Gdf-15)
  • Methods Of Using Fc-Cytokine Fusion Proteins
  • Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells
  • Anti-Igf-Ir Antibodies And Uses Thereof
  • Humanized Anti-Tgf-Beta Antibodies
  • Anti-Ganglioside Antibodies And Compositions
  • Borrelia Antigens
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Humanized Anti-Tag-72 Monoclonal Antibodies
  • Methods And Compositions For Detecting Polynucleotides
  • Reducing The Immunogenicity Of Fusion Proteins
  • Communications Network System And Methods For Using Same
  • Alpha-Fetoprotein Immu31 Antibodies And Fusion Proteins And Methods Of Use Thereof
  • Pseudomonas Aeruginosa Pcrv Binding Single Variable Domain Antibodies
  • Enzymatic Conjugation Of Polypeptides
  • Methods Of Use Of Anti-Cd19 Antibodies With Reduced Immunogenicity
  • Anti-Cd79b Antibodies And Immunoconjugates And Methods Of Use
  • Compositions And Methods Relating To Universal Glycoforms For Enhanced Antibody Efficacy
  • Monoclonal Antibodies Against Tumor-Associated Antigens, A Process For The Preparation Thereof And The Use Thereof
  • Antibodies Against Claudin 18.2 Useful In Cancer Diagnosis
  • Variants Of Cellobiohydrolases
  • Anti-Dll3 Antibody Drug Conjugates And Methods Of Use
  • Diagnostic Method For Determining The Presence And Amount Of Human Interleukin-3 In A Sample Using Novel Il-3 Antibodies
  • Antibody Producing Non-Human Mammals
  • A Blocking Monoclonal Antibody To Vla-1 And Its Use For The Treatment Of Vascular Disorders
  • Humanized Antibodies Against Tl1a
  • Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus
  • Anti-Ngf Antibodies And Methods Using Same
  • Antibodies Which Bind B7rp1
  • Anti-Cancer Antibodies With Reduced Complement Fixation
  • Nucleic Acids Encoding Human Monoclonal Antibodies To Ctla-4
  • Artificial Antibody Polypeptides
  • Hybrid Antibodies
  • Antibody With Protein A Selectivity
  • Diagnostic Antibody Assay
  • Apaf-1 An Activator Of Caspase-3
  • Method For Tapping The Immunological Repertiore
  • Method For Producing Polymers Having A Preselected Activity
  • Hepatocyte Growth Factor Receptor Agonists And Uses Thereof
  • O-Fucosyltransferase
  • Anti-Amyloid Antibodies And Uses Thereof
  • Antibodies To Matrix Metalloproteinase 9
  • Antibodies To Phosphorylated Tau Aggregates
  • Combination Therapy With Anti-Cd74 Antibodies Provides Enhanced Toxicity To Malignancies, Autoimmune Disease And Other Diseases
  • Proteins Comprising An Igg2 Domain
  • Anti-Glucosaminidase Passive Immunization For Staphylococcus Aureus Infections
  • Neuropilin Antagonists
  • Composition And Method For Enhancing Fibrinolysis
  • Methods And Monitoring Of Treatment With A Dll4 Antagonist
  • Spliceostatin Analogs And Methods For Their Preparation
  • Peptides Derived From Cytotoxicity Receptor Natural Killer Protein 44 Nkp44
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Methods For Viral Inactivation And Other Adventitious Agents
  • Gitr Antibodies And Methods Of Inducing Or Enhancing An Immune Response
  • Endoglin Antibodies
  • Anti-Mesothelin Antibodies
  • Anti-Dll3 Antibodies
  • Anti Notch-1 Antibodies
  • Methods Of Making Antibody Heavy And Light Chains Having Specificity For A Desired Antigen
  • Combination Therapy With Co-Stimulatory Factors
  • Bgl3 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Anti-Vegf Antibodies
  • Anti-Interferon-Α Antibodies
  • Protein, Method For Immobilizing Protein, Structure, Biosensor, Nucleic Acid, Vector And Kit For Detecting Target Substance
  • Labeled Peptides, Proteins And Antibodies And Processes And Intermediates Useful For Their Preparation
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Β-Glucosidase 5 (Bgl5) Compositions
  • Super Humanized Antibodies
  • Methods And Compositions For Modulating T Helper (Th) Cell Development And Function
  • Egvi Endoglucanase And Nucleic Acids Encoding The Same
  • Method Of Inducing Apoptosis By Reducing The Level Of Thiamin
  • Anti-Dll4 Antibodies And Methods Using Same
  • Methods For Stabilizing Protein Solutions
  • Human Monoclonal Antibodies To Ctla-4
  • Human Anti-Ifn-Γ Neutralizing Antibodies As Selective Ifn-Γ Pathway Inhibitors
  • Fragments Of Antibodies To Epidermal Growth Factor Receptor And Methods Of Their Use
  • Kid3 And Kid3 Antibodies That Bind Thereto
  • Immunoglobulin Variants And Uses Thereof
  • Antibodies To Stra6 Polypeptides
  • Methods Of Expanding Stem And Progenitor Cells And Expanded Cell Populations Obtained Thereby
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Immunotoxins Comprising Ribosome-Inactivating Proteins
  • O-Fucosyltransferase
  • Genetic Alterations Related To Familial Alzheimer's Disease
  • Pcr Amplification Of Rearranged Genomic Variable Regions Of Immunoglobulin Genes
  • Borrelia Antigens
  • Anti-Cd74 Immunoconjugates And Methods Of Use
  • Humanized Anti-Tag-72 Monoclonal Antibodies
  • Protein, Method For Immobilizing Protein, Structure, Biosensor, Nucleic Acid, Vector And Kit For Detecting Target Substance
  • Totally Synthetic Affinity Reagents
  • Apo-2 Ligand
  • Bioassay Using Alk-7, A Novel Serine Threonine Kinase Receptor
  • Immunotoxins Comprising Ribosome-Inactivating Proteins
  • Hepatocyte Growth Factor Receptor Antagonists And Uses Thereof
  • Human Growth Hormone Variants
  • Proteins Encoding Gelonin Sequences
  • Immunotoxins Comprising Ribosome-Inactivating Proteins
  • Uses Of Wnt Polypeptides
  • Humanized Antibodies
  • O-Fucosyltransferase
  • Genetic Alterations Related To Familial Alzheimer's Disease
  • Pcr Amplification Of Rearranged Genomic Variable Regions Of Immunoglobulin Genes
  • Pseudomonas Aeruginosa Pcrv Binding Single Variable Domain Antibodies
  • Enzymatic Conjugation Of Polypeptides
  • Methods Of Use Of Anti-Cd19 Antibodies With Reduced Immunogenicity
  • Antibodies Against Claudin 18.2 Useful In Cancer Diagnosis
  • Anti-Cgrp Compositions And Use Thereof
  • Culturing Of Mesenchymal Stem Cells With Fgf4 And Nicotinamide
  • Nucleic Acids Encoding Hepatocyte Growth Factor Receptor Antagonist Antibodies
  • Immunotoxins Comprising Ribosome-Inactivating Proteins
  • Modified Antibody Variable Domains
  • Vectors With Pectate Lyase Signal Sequence
  • Polynucleotides Encoding Gelonin Sequences
  • Methods And Compositions For Inhibiting Cd32b Expressing Cells
  • Immunoglobulins And Variants Directed Against Pathogenic Microbes
  • Chimeric Ospa Genes, Proteins And Methods Of Use Thereof
  • Synthetic Immunoglobulin Domains With Binding Properties Engineered In Regions Of The Molecule Different From The Complementarity Determining Regions
  • Guidewire Artifact Removal In Images
  • Humanized Antibodies
  • Anti-Ige Antibodies
  • Erythropoietin Forms With Improved Properties
  • Polynucleotides Encoding Humanized Antibodies Against Human 4-1bb
  • Antibodies That Bind To Cancer-Associated Antigen Cd46 And Methods Of Use Thereof
  • Regulation Of Endogenous Gene Expression In Cells Using Zinc Finger Proteins
  • Dual Expression Vector System For Antibody Expression In Bacterial And Mammalian Cells
  • Chemokine Receptor Able To Bind To Mcp-1, Mip-1 Α And/Or Rantes And Its Uses
  • Optical Coherence Tomography System That Is Reconfigurable Between Different Imaging Modes
  • Systems And Methods For Amplifying Light
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Antibodies Specific For Tgf-Β And Methods Of Treatment Thereof
  • Biomarker Of Asbestos Exposure And Mesothelioma
  • S. Pneumoniae Antigens
  • Altered Antibodies And Their Preparation
  • Methods To Increase Or Decrease Bone Density
  • Antibodies To Lymphotoxin-Α
  • Egviii Endoglucanase And Nucleic Acids Encoding The Same
  • Regulation Of Endogenous Gene Expression In Cells Using Zinc Finger Proteins
  • Hepatocyte Growth Factor Receptor Antagonists And Uses Thereof
  • Methods Of Optimizing Antibody Variable Region Binding Affinity
  • Thermomyces Lanuginosus Kinesin Motor Protein And Methods Of Screening For Modulators Of Kinesin Proteins
  • Interleukin-5 Specific Recombinant Antibodies
  • Macrophage Derived Chemokine (Mdc) And Chemokine Analogs And Assay To Identify Modulators Of Mdc Activity, And Therapeutic Uses For Same
  • Regulation Of Endogenous Gene Expression In Cells Using Zinc Finger Proteins
  • Psca: Prostate Stem Cell Antigen And Uses Thereof
  • Regulation Of Endogenous Gene Expression In Cells Using Zinc Finger Proteins
  • Modulators Of Expression And Function Of Lrp In Alzheimer's Disease
  • Altered Antibodies
  • C5-Specific Antibodies For The Treatment Of Inflammatory Diseases
  • Methods And Host Cells For Producing Human Monoclonal Antibodies To Ctla-4
  • Human Anti-Ifn-Γ Neutralizing Antibodies As Selective Ifn-Γ Pathway Inhibitors
  • Production Of Anti-Abeta
  • Gamma-1 And Gamma-3 Anti-Human Cd23 Monoclonal Antibodies And Use Thereof As Therapeutics
  • Production Of Polypeptides
  • Variants Of Humanized Anti-Carcinoma Monoclonal Antibody Cc49
  • Methods For Treating Post-Surgical Pain By Administering An Anti-Nerve Growth Factor Antagonist
  • Bgl4 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Compositions And Methods Relating To Universal Glycoforms For Enhanced Antibody Efficacy
  • Anti-Her2 Glycoantibodies And Uses Thereof
  • Self-Assembled Fmoc-Ff Hydrogels
  • Method For Inhibiting The Immune Suppressive Function Of Human T Regulatory Cells By Administering An Anti-Garp Monoclonal Antibody
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Decreasing Lactate Level And Increasing Polypeptide Production By Downregulating The Expression Of Lactate Dehydrogenase And Pyruvate Dehydrogenase Kinase
  • Immunological Targeting Of Pathological Tau Proteins
  • Apo-3 Polypeptide
  • Altered Antibodies
  • Anti-Fgfr3 Antibodies And Methods Using Same
  • Composition And Method For Enhancing Fibrinolysis Using Antibodies To Alpha-2-Antiplasmin
  • Hybridoma And Anti-Kc-4 Humanized Monoclonal Antibody, Dna And Rna Encoding It, Kit, Diagnostic And Therapeutic Methods
  • Composition And Method For Enhancing Fibrinolysis
  • Anti-Ngf Antibodies And Methods Using Same
  • Antibodies Which Bind B7rp1
  • Anti-Cancer Antibodies With Reduced Complement Fixation
  • Antibody With Protein A Selectivity
  • Treating Autoimmune Diseases With Humanized Anti-Cd40l Antibody
  • Identification And Expression Of A Novel Kinesin Motor Protein
  • Antigen Pipa And Antibodies That Bind Thereto
  • Fragments And Variants Of Staphylococcus Aureus Dnag Primase, And Uses Thereof
  • Non-Affinity Purification Of Proteins
  • Anti-Ox40l Antibodies
  • Entropic Bristle Domain Sequences And Their Use In Recombinant Protein Production
  • Anti-Galanin Antibodies And Uses Thereof
  • Anti-Angiogenic Compounds
  • Biomarkers
  • Beta Secretase Genes
  • Angiogenesis Inhibiting Molecules, Their Selection, Production And Their Use In The Treatment Of Cancer
  • Vegfr-3 Fusion Proteins
  • Methods For Purifying A Target Protein From One Or More Impurities In A Sample
  • Methods To Determine Immunogenicity Of Humanized Anti-Tag 72 Cc49 Antibodies
  • Met-Binding Agents And Uses Thereof
  • Compositions And Methods For The Treatment Of Tumor Of Hematopoietic Origin
  • Anti-Dll3 Antibody Drug Conjugates And Methods Of Use
  • Functional Heavy Chain Antibodies, Fragments Thereof, Library Thereof And Methods Of Production Thereof
  • Proteins Comprising An Igg2 Domain
  • Anti-Glucosaminidase Passive Immunization For Staphylococcus Aureus Infections
  • Anti-Amyloid Antibodies And Uses Thereof
  • Chimeric Antigen Receptor Specific For Folate Receptor Β
  • Peptides And Methods Using Same For Diagnosis And Treatment Of Amyloid-Associated Disease
  • Neuropilin Antagonists
  • Anti-Dll3 Antibodies
  • Anti Notch-1 Antibodies
  • Endoglin Antibodies
  • Anti-Mesothelin Antibodies
  • Signal Biomarkers
  • B7rp-1 Antagonists
  • Cell Targeting Methods And Compositions
  • Genetically Modified Human Natural Killer Cell Lines
  • Anti-Il-6r Polypeptides And Pharmaceutical Compositions Thereof
  • Method For Selecting A Single Cell Expressing A Heterogeneous Combination Of Antibodies
  • Il-17 Binding Proteins
  • Enhancing Activity Of Car T Cells By Co-Introducing A Bispecific Antibody
  • Anti-Human Igg1 Antibody
  • Antibody Constructs For Cdh19 And Cd3
  • Multiple Signaling Pathways Induced By Hexavalent, Monospecific And Bispecific Antibodies For Enhanced Toxicity To B-Cell Lymphomas And Other Diseases
  • Cytotoxic Immunoglobulin
  • Recombinant Human Anti-Cd18 Antibodies
  • Rnai Vitamin D Conjugates
  • Methods For Treating Melanoma
  • Anti-Dll3 Antibody Drug Conjugates
  • Glypican-3-Specific Antibody And Uses Thereof
  • Stem Cell Factor Inhibitor
  • Humanized Anti-Factor D Antibodies And Uses Thereof
  • Blocking Il-9 Signaling In Conjunction With Chemotherapy To Treat Cancer
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Engineered Anti-Il-23 Antibodies
  • Neuritogenic Peptides
  • Inhibition And Treatment Of Prostate Cancer Metastasis
  • Anti-Mesothelin Antibodies
  • Antibodies And Their Use In The Treatment, Prevention And Diagnosis Of A Disease Associated With Sod1 Abnormalities
  • Modulators Of Hepatocyte Growth Factor Activator
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Anti-Jam-A Antibodies
  • Intranasal Administration Of Active Agents To The Central Nervous System
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Biofilm Treatment
  • Kits For Multiparametric Phospho Analysis
  • Endoglin Antibodies
  • Humanized Antibodies To Ganglioside Gm2
  • Pectate Lyase Signal Sequence
  • Cytotoxic Peptides And Antibody Drug Conjugates Thereof
  • Zanamivir Phosphonate Congeners With Anti-Influenza Activity And Determining Oseltamivir Susceptibility Of Influenza Viruses
  • Methods Of Modulating Adrenomedullin By Administering An Anti-Adrenomedullin (Adm) Antibody
  • Antibody-Sn-38 Immunoconjugates With A Cl2a Linker
  • Compositions And Methods For Diagnosing And Treating Cancer
  • Anti-Semaphorin 3a Antibody And Treatment Of Alzheimer's Disease And Inflammatory Immune Diseases Using Same
  • Methods Of Detecting Factor D With Anti-Factor D Antibodies
  • Methods Of Treating Cancer With Human Monoclonal Antibodies To Ctla-4
  • Display Of Binding Agents
  • Therapeutic Composition For Treatment Of Glioblastoma
  • Multivalent Dll3 Antibodies
  • Method And Apparatus To Identify Vulnerable Plaques With Thermal Wave Imaging Of Heated Nanoparticles
  • Borrelia Antigens
  • Stable Igg4 Based Binding Agent Formulations
  • Artificial Antibody Polypeptides
  • Nucleic Acid Encoding Dll3 Antibodies
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Catheter For In Vivo Imaging
  • Anti-Notch1 Antibodies
  • Methods Of Generating Libraries And Uses Thereof
  • Antibodies To Matrix Metalloproteinase 9
  • Nanobodies Against Tumor Necrosis Factor-Alpha
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Antibodies To Carcinoembryonic Antigen (Cea), Methods Of Making Same, And Uses Thereof
  • Compositions And Methods For Treating And Diagnosing Pancreatic Cancer
  • Her-3 Antibodies And Methods Of Use
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Ionic Strength-Mediated Ph Gradient Ion Exchange Chromatography
  • Antibodies That Specifically Bind To Alk-7, A Novel Serine Threonine Kinase Receptor
  • Monoclonal Antibodies Against Tumor-Associated Antigens
  • Multiplex Protein Fractionation
  • Super Humanized Antibodies
  • Factor Ix/Factor Ixa Activating Antibodies And Antibody Derivatives
  • Humanized Anti-Cea T84.66 Antibody And Uses Thereof
  • Cancer Treatment And Monitoring Methods Using Ox40 Agonists
  • Antibodies To The C3d Fragment Of Complement Component 3
  • Humanized Anti-Cxcr5 Antibodies, Derivatives Thereof And Their Uses
  • Alkynyl Sugar Analogs For Labeling And Visualization Of Glycoconjugates In Cells
  • Production Of Heteromultimeric Proteins
  • Optical-Electrical Rotary Joint And Methods Of Use
  • Methods Of Making Dll3 Antibody Drug Conjugates
  • High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
  • Carriers For Improved Drug Delivery
  • Anti-Dll3 Antibody Drug Conjugates
  • Combining Anti-Hla-Dr Or Anti-Trop-2 Antibodies With Microtubule Inhibitors, Parp Inhibitors, Bruton Kinase Inhibitors Or Phosphoinositide 3-Kinase Inhibitors Significantly Improves Therapeutic Outcome In Cancer
  • Anti-Tissue Factor Antibodies And Compositions
  • Pd-1 Specific Antibodies And Uses Thereof
  • Combining Anti-Hla-Dr Or Anti-Trop-2 Antibodies With Microtubule Inhibitors, Parp Inhibitors, Bruton Kinase Inhibitors Or Phosphoinositide 3-Kinase Inhibitors Significantly Improves Therapeutic Outcome In Cancer
  • Anti-Tissue Factor Antibodies And Compositions
  • Optical-Electrical Rotary Joint And Methods Of Use
  • Methods Of Making Dll3 Antibody Drug Conjugates
  • High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
  • Crosslinking Of Cd22 By Epratuzumab Triggers Bcr Signaling And Caspase-Dependent Apoptosis In Hematopoietic Cancer Cells
  • Coagulation Factor Ix Compositions And Methods Of Making And Using Same
  • Immunology Treatment For Biofilms
  • Kid3 And Kid3 Antibodies That Bind Thereto
  • Cd37 Immunotherapeutics And Uses Thereof
  • Bgl3 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Reconstituted Polypeptides
  • Porphyromonas Gingivalis Polypeptides And Nucleotides
  • Heterodimeric Fusion Proteins Useful For Targeted Immune Therapy And General Immune Stimulation
  • Peptides Which Bind To G Protein-Coupled Receptors
  • Method For Tapping The Immunological Repertoire
  • Chimeric Anti-Vegf-D Antibodies And Humanized Anti-Vegf-D Antibodies And Methods Of Using Same
  • Therapeutic Targets In Cancer
  • Gpr30 Estrogen Receptor In Breast Cancers
  • Anti-Α2 Integrin Antibodies And Their Uses
  • Apo-2 Receptor Agonist Antibodies
  • Medical Devices And Methods For Local Delivery Of Angiotensin Ii Type 2 Receptor Antagonists
  • Method For Using Antibodies For Inhibiting Blood Coagulation
  • Microarray And Uses Therefor
  • Variable Domain Library And Uses
  • Covalent Diabodies And Uses Thereof
  • Immunocytokine Sequences And Uses Thereof
  • Cxc-Chemokine Antagonists Isolated From Rhipicephalus Sanguineus
  • Methods For Treating Pain By Administering A Nerve Growth Factor Antagonist And An Nsaid
  • Methods To Increase Or Decrease Bone Density
  • Uses Of A Chemokine Receptor Able To Bind To Mcp-1, Mip-1Α And/Or Rantes
  • Anti-Vegf Antibodies
  • Humanized Antibodies
  • Labeled Peptides, Proteins And Antibodies And Processes And Intermediates Useful For Their Preparation
  • Compositions And Methods In Cancer Associated With Altered Expression Of Kcnj9
  • Zinc Finger Proteins For Dna Binding And Gene Regulation In Plants
  • Method Of Humanizing Antibodies By Matching Canonical Structure Types Cdrs
  • Junctional Adhesion Molecule-C (Jam-C) Binding Compounds And Methods Of Their Use
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Feeding Formula Appliance
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Erbb3 Binding Antibody
  • Purification Of A Bivalently Active Antibody Using A Non-Chromatographic Method
  • Kid31 And Antibodies That Bind Thereto
  • Artificial Antibody Polypeptides
  • Expansion Of Renewable Stem Cell Populations
  • Met Fab And Scfv Fragments
  • Artificial Antibody Polypeptides
  • Method For Making Humanized Antibodies
  • Methods Of Treating Diabetes And Compositions Capable Of Same
  • Novel Antibody Derivatives
  • Hgf Β Chain Variants
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Cancerous Disease Modifying Antibodies
  • Aptamer Therapeutics Useful In The Treatment Of Complement-Related Disorders
  • Antibodies Directed Against Amyloid-Beta Peptide
  • Anti-Neoplastic Uses Of Artemin Antagonists
  • Stra6 Polypeptides
  • Simultaneous Modulation Of Multiple Genes
  • Dual Variable Domain Immunoglobulin And Uses Thereof
  • Humanized Antibodies Against Tl1a
  • Variant Hypocrea Jecorina Cbh1 Cellulases
  • Synthetic Antibody Phage Libraries
  • Stirred Tank Bioreactor
  • Modified Zinc Finger Binding Proteins
  • Cell Culture Media And Methods Of Antibody Production
  • Antibodies Reactive With B7-H3 And Uses Thereof
  • Antibodies That Bind Il-4 And/Or Il-13 And Their Uses
  • Composition And Methods Of Treating B Cell Disorders
  • Bh3 Peptides And Methods Of Use Thereof
  • Generating Targeted Sequence Diversity In Fusion Proteins
  • High-Throughput Antibody Humanization
  • Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes
  • Yersinia Spp. Polypeptides And Methods Of Use
  • Methods For Stimulating Hematopoietic Recovery By Inhibiting Tgfβ Signaling
  • Antibodies To Bradykinin B1 Receptor Ligands
  • Binding Domains Of Proteins Of The Repulsive Guidance Molecule (Rgm) Protein Family And Functional Fragments Thereof, And Their Use
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Ferroportin Antibodies And Methods Of Use
  • Systems And Methods For Narrowing A Wavelength Emission Of Light
  • Prostaglandin E2 Dual Variable Domain Immunoglobulins And Uses Thereof
  • Anti-Cd19 Antibodies With Reduced Immunogenicity
  • Cysteine Engineered Anti-Tenb2 Antibodies And Antibody Drug Conjugates
  • Antibodies Against Kidney Associated Antigen 1 And Antigen Binding Fragments Thereof
  • Methods Of Improving Stem Cell Homing And Engraftment
  • Il-1 Binding Proteins
  • Anti-Dll3 Antibody Drug Conjugates
  • Methods Of Treating Of Diabetes And Obesity Using Fgf21 Mutants
  • Site-Specific Antibody Conjugation Methods And Compositions
  • Cell Culture Compositions With Antioxidants And Methods For Polypeptide Production
  • Antigenic Gm-Csf Peptides And Antibodies To Gm-Csf
  • Bifunctional Cytotoxic Agents
  • Anti-Sortilin Antibodies And Methods Of Use Thereof
  • Uses Of Antibodies To Aminophospholipids For Cancer Treatment
  • Antibodies And Derivatives Thereof
  • Anti-Cgrp Compositions And Use Thereof
  • Use Of Anti-Cgrp Antibodies And Antibody Fragments To Treat Diarrhea In Subjects With Diseases Or Treatments That Result In Elevated Cgrp Levels
  • Anti-Dll3 Antibody Drug Conjugates
  • Methods Of Making Dll3 Antibody Drug Conjugates
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Bh3 Peptides And Methods Of Use Thereof
  • Anti-Dll3 Antibody Drug Conjugates
  • Cell Culture Compositions With Antioxidants And Methods For Polypeptide Production
  • Antigenic Gm-Csf Peptides And Antibodies To Gm-Csf
  • Bifunctional Cytotoxic Agents
  • Anti-Sortilin Antibodies And Methods Of Use Thereof
  • Compositions And Methods For Treatment And Detection Of Cancers
  • Recombinant Antibodies And Methods For Their Production
  • Recombinant Antibodies And Methods For Their Production
  • Antibodies To Bradykinin B1 Receptor Ligands
  • Cd3-Binding Molecules Capable Of Binding To Human And Non-Human Cd3
  • High-Throughput Antibody Humanization
  • Cell Culture Media And Methods Of Antibody Production
  • Antibodies Reactive With B7-H3 And Uses Thereof
  • Anti-Cgrp Compositions And Use Thereof
  • Antibodies That Bind Il-4 And/Or Il-13 And Their Uses
  • Antibodies And Derivatives Thereof
  • Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes
  • Anti-Dll3 Antibody Drug Conjugates
  • Methods For Stimulating Hematopoietic Recovery By Inhibiting Tgfβ Signaling
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Alpha-Fetoprotein Immu31 Antibodies And Fusion Proteins And Methods Of Use Thereof
  • Repressing Endogenous Ccr5 Gene Expression In Cells Using Engineered Zinc Finger Proteins
  • Methods Of Identifying Agents That Modulate The Binding Between Mdc And An Mdc Receptor
  • Monoclonal Antibodies Against Tumor-Associated Antigens, Processes For The Preparation Thereof And The Use Thereof
  • Therapeutic Dll4 Binding Proteins
  • Biomarkers
  • Homeobox Gene
  • Human Alpha-Folate Receptor Chimeric Antigen Receptor
  • Benzocyclooctyne Compounds And Uses Thereof
  • Compositions And Methods For Treating And Diagnosing Pancreatic Cancer
  • Filipil Compositions And Methods For Treating Cancer
  • Magneto-Motive Ultrasound Detection Of Magnetic Nanoparticles
  • Ilt3 Binding Molecules And Uses Therefor
  • Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof
  • Antibodies Reactive With B7-H3 And Uses Thereof
  • Enzymatic Conjugation Of Polypeptides
  • Enhanced Protein Purification Through A Modified Protein A Elution
  • Multivalent Antibodies And Uses Therefor
  • Methods Of Detection, Diagnosis, And Monitoring Using Anti-Dll3 Antibodies
  • Use Of Anti-Cd83 Agonist Antibodies For Treating Autoimmune Diseases
  • Anti-Adrenomedullin (Adm) Antibody Or Anti-Adm Antibody Fragment For Use In Therapy
  • Fully Human, Anti-Mesothelin Specific Chimeric Immune Receptor For Redirected Mesothelin-Expressing Cell Targeting
  • Endoglin Antibodies
  • Chimeric Fibroblast Growth Factors With Altered Receptor Specificity
  • Transgenic Mammals Having Human Ig Loci Including Plural Vh And Vκ Regions And Antibodies Produced Therefrom
  • Method Of Treating An Ischemia-Reperfusion Injury-Related Disorder By Administering Gpcr Ligands
  • Anti-Inflammatory Dab
  • Human Monoclonal Antibodies To Ctla-4
  • Neuropilin Antagonists
  • Flt4 (Vegfr-3) As A Target For Tumor Imaging And Anti-Tumor Therapy
  • Insulin Vitamin D Conjugates
  • Method Of Treatment Using Humanized Anti-Cd11a Antibodies
  • Methods And Compositions Of Matter Concerning April/G70, Bcma, Blys/Agp-3 And Taci
  • Growth Hormone Variants
  • Cytokine Receptor And Nucleic Acids Encoding The Same
  • Drosophila G Protein Coupled Receptors, Nucleic Acids, And Methods Related To The Same
  • Anti-Ige Antibodies
  • Apo-2li And Apo-3 Polypeptides
  • Treatment For Inflammatory Bowel Disease With A Vcam-1/1gg Fusion Protein
  • Totally Synthetic Affinity Reagents
  • Nucleic Acid Encoding Amyloid Precursor-Like Protein And Uses Thereof
  • Human Monoclonal Antibody Specifically Binding To Surface Antigen Of Cancer Cell Membrane
  • Method For Identifying Active Domains And Amino Acid Residues In Polypeptides And Hormone Variants
  • Uses Of Antibodies To Aminophospholipids For Cancer Treatment
  • Chimeric Antibody With Specificity To Human B Cell Surface Antigen
  • Methods Of Modulating Lipid Metabolism And Storage
  • Human Monoclonal Antibody Specifically Binding To Surface Antigen Of Cancer Cell Membrane
  • Chimeric Antibody With Specificity To Human B Cell Surface Antigen
  • Polynucleotides Encoding The Anti-Pem Antibody Bw835 Variable Domains And Expression Vectors
  • Totally Synthetic Affinity Reagents
  • Met Fab And Scfv Fragments
  • Artificial Antibody Polypeptides
  • Expansion Of Renewable Stem Cell Populations
  • Stra6 Polypeptides
  • Simultaneous Modulation Of Multiple Genes
  • Antibodies Directed Against Amyloid-Beta Peptide
  • Anti-Neoplastic Uses Of Artemin Antagonists
  • Variable Domain Library And Uses
  • Gpr30 Estrogen Receptor In Breast Cancers
  • Therapeutic Targets In Cancer
  • Anti-Α2 Integrin Antibodies And Their Uses
  • Apo-2 Receptor Agonist Antibodies
  • Microarray And Uses Therefor
  • Heterodimeric Fusion Proteins Useful For Targeted Immune Therapy And General Immune Stimulation
  • Peptides Which Bind To G Protein-Coupled Receptors
  • Junctional Adhesion Molecule-C (Jam-C) Binding Compounds And Methods Of Their Use
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Feeding Formula Appliance
  • Variant Hypocrea Jecorina Cbh1 Cellulases
  • Synthetic Antibody Phage Libraries
  • Method For Tapping The Immunological Repertoire
  • Method For Using Antibodies For Inhibiting Blood Coagulation
  • Medical Devices And Methods For Local Delivery Of Angiotensin Ii Type 2 Receptor Antagonists
  • Chimeric Anti-Vegf-D Antibodies And Humanized Anti-Vegf-D Antibodies And Methods Of Using Same
  • Immunocytokine Sequences And Uses Thereof
  • Covalent Diabodies And Uses Thereof
  • Method Of Humanizing Antibodies By Matching Canonical Structure Types Cdrs
  • Anti-Vegf Antibodies
  • Compositions And Methods In Cancer Associated With Altered Expression Of Kcnj9
  • Zinc Finger Proteins For Dna Binding And Gene Regulation In Plants
  • Humanized Antibodies
  • Methods Of Making Dll3 Antibody Drug Conjugates
  • Methods Of Determining Patient Response By Measurement Of Her-3 And P95
  • Antibody Producing Non-Human Mammals
  • Dual Specific Binding Proteins Directed Against Il-1Β And/Or Il-17
  • Antibodies Against Kidney Associated Antigen 1 And Antigen Binding Fragments Thereof
  • Material And Methods For Treating Or Preventing Her-3 Associated Diseases
  • Multimodal Segmentation In Intravascular Images
  • Polypeptides And Immunizing Compositions Containing Gram Positive Polypeptides And Methods Of Use
  • Anti-Gd2 Antibodies
  • Hla-Dr Specific Antibodies, Compositions And Methods
  • Antibodies To Clostridium Difficile Spores And Uses Thereof
  • Methods And Compositions For Increasing Antibody Production
  • Treatment Of Cancer Using Anti-Apo-2 Antibodies
  • Humanized Anti-Cea T84.66 Antibody And Uses Thereof
  • Compositions And Methods In Cancer Associated With Altered Expression Of Prlr
  • Intrabodies With Defined Framework That Is Stable In A Reducing Environment And Applications Thereof
  • Bgl4 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • S. Pneumoniae Antigens
  • Compositions Capable Of Specifically Binding Particular Human Antigen Presenting Molecule/Pathogen-Derived Antigen Complexes And Uses Thereof
  • Antibacterial Agents And Methods Of Identifying And Utilizing Same
  • Anti-Vegf Antibodies
  • Anti-Ox40l Antibodies
  • Method For Making Heteromultimeric Molecules
  • Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
  • Antibodies To Bradykinin B1 Receptor Ligands
  • B7-H1 Antibodies And Method Of Use
  • Co-Use Of A Clusterin Inhibitor With An Egfr Inhibitor To Treat Cancer
  • Bispecific Antibodies That Bind To Cd38 And Cd3
  • Method Of Treatment Of A Solid Tumor With Interleukin-1 Accessory Protein Antibody
  • Dual Specific Binding Proteins Directed Against Il-13 And Il-17
  • Treatment Of Allergic Diseases With Recombinant Antibodies
  • Anti-Siglec-8 Antibodies And Methods Of Use Thereof
  • Human Monoclonal Antibodies Against Cd25
  • Removal Of A-Scan Streaking Artifact
  • Genetically Modified Human Natural Killer Cell Lines
  • High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
  • Modified Zinc Finger Binding Proteins
  • Use Of Complement Inhibitors To Treat Ocular Diseases
  • Antibodies Inhibiting C-Met Dimerization, And Uses Thereof
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Il-1 Binding Proteins
  • Methods Of Treating With Anti-Factor D Antibodies
  • Fgf21 Mutants And Uses Thereof
  • Therapeutic Dll4 Binding Proteins
  • Angiogenesis Inhibiting Molecules, Their Selection, Production And Their Use In The Treatment Of Cancer
  • Monoclonal Antibodies Against Tumor-Associated Antigens, A Process For The Preparation Thereof And The Use Thereof
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Treating Allergic Diseases With Humanized Anti-Cd40l Antibody
  • Human Monoclonal Antibody Specifically Binding To Surface Antigen Of Cancer Cell Membrane
  • Human Monoclonal Antibody Specifically Binding To Surface Antigen Of Cancer Cell Membrane
  • Antigen Binding Molecules That Bind Egfr, Vectors Encoding Same, And Uses Thereof
  • Anti-Alpha2 Integrin Antibodies And Their Uses
  • Human M2e Peptide Immunogens
  • Bacterially-Derived, Intact Minicells That Encompass Plasmid-Free Functional Nucleic Acid For In Vivo Delivery To Mammalian Cells
  • Engineered Anti-Il-23p19 Antibodies
  • Production Of Proteins In Glutamine-Free Cell Culture Media
  • Anti-Cd74 Immunoconjugates And Methods
  • Anti-Veev Humanized Antibody
  • Humanized Anti-Factor D Antibodies And Uses Thereof
  • Multispecific Antibodies Comprising Full Length Antibodies And Single Chain Fab Fragments
  • Monoclonal Antibody Capable Of Binding Integrin Alpha 10 Beta 1
  • Systems And Methods For Generating Images Of Tissue
  • Piscine Reovirus Diagnostic Compositions
  • Adam-9 Modulators
  • Antibodies That Bind To Epha2 And Methods Of Use Thereof
  • Recombinant Prion-Like Proteins And Materials Comprising Same
  • Modified Vaccinia Ankara Expressing P53 In Cancer Immunotherapy
  • Bgl6 Beta-Glucosidase And Nucleic Acids Encoding The Same
  • Position Dependent Recognition Of Gnn Nucleotide Triplets By Zinc Fingers
  • Flt4 (Vegfr-3) As A Target For Tumor Imaging And Anti-Tumor Therapy
  • Transgenic Animals For Producing Specific Isotypes Of Human Antibodies Via Non-Cognate Switch Regions
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Anti-Fatty Acid Amide Hydrolase-2 Antibodies And Uses Thereof
  • Assembly Of Bispecific Antibodies
  • Interleukin-6 Receptor Binding Polypeptides
  • Generating Targeted Sequence Diversity In Proteins
  • Egvii Endoglucanase And Nucleic Acids Encoding The Same
  • Hedgehog And Patched Antagonists For Inhibiting Cell And Tissue Growth And Differentiation And Uses Therefor
  • Antibodies To Oncostatin M Receptor
  • Nucleic Acids Coding For Antibodies Against Human Il-21 Receptor And Uses Therefor
  • Anti-Bv8 Antibodies And Uses Thereof
  • Modulation Of Endogenous Gene Expression In Cells
  • Neutralizing Monoclonal Antibodies To Respiratory Syncytial Virus
  • Anti Ceacam1 Antibodies And Methods Of Using Same
  • Vegf/Dll4 Binding Agents And Uses Thereof
  • B7-H1 And Methods Of Diagnosis, Prognosis, And Treatment Of Cancer
  • Treating A Mammal With A Formulation Comprising An Antibody Which Binds Ige
  • Nucleic Acids Encoding Il-6r-Binding Polypeptides
  • Identification And Expression Of A Novel Kinesin Motor Protein
  • Humanized Antibodies
  • Bgl5 Β-Glucosidase And Nucleic Acids Encoding The Same
  • Coagulation Factor Ix Compositions And Methods Of Making And Using Same
  • Anti-Spla2-Iia Antibodies And Uses Thereof
  • Antibodies Targeting Hiv Escape Mutants
  • Il-17 Binding Proteins
  • Antibodies Against Claudin 18.2 Useful In Cancer Diagnosis
  • Anti-Dll3 Antibody Drug Conjugates
  • Humanized Anti Cxcr4 Antibodies For The Treatment Of Cancer
  • Immunoglobulin Chimeric Monomer-Dimer Hybrids
  • Monoclonal Antibodies Against Tumor-Associated Antigens, A Process For The Preparation Thereof And The Use Thereof
  • Antibodies Targeting Hiv Escape Mutants
  • Treating Allergic Diseases With Humanized Anti-Cd40l Antibody
  • Anti-Vegf Antibodies
  • Polynucleotides Encoding Anti-Cd20 Antigen Binding Molecules With Increased Fc Receptor Binding Affinity And Effector Function
  • Dosages Of Immunoconjugates Of Antibodies And Sn-38 For Improved Efficacy And Decreased Toxicity
  • Anti-Cancer Antibodies With Reduced Complement Fixation
  • Il-17 Binding Proteins
  • Methods Of Diagnosing Acute Cardiac Disorders Using Bnp-Sp
  • Methods For Treating Bone Cancer By Administering A Nerve Growth Factor Antagonist Antibody
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/321522a0

    DOI

    http://dx.doi.org/10.1038/321522a0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1007617918

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/3713831


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Amino Acid Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Base Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Genes", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin E", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin Variable Region", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Models, Molecular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Myeloma Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Plasmids", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Conformation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Species Specificity", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "familyName": "Jones", 
            "givenName": "Peter T.", 
            "id": "sg:person.0630656334.35", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630656334.35"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Dear", 
            "givenName": "Paul H.", 
            "id": "sg:person.016667736115.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016667736115.82"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Foote", 
            "givenName": "Jefferson", 
            "id": "sg:person.01317103576.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317103576.22"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Neuberger", 
            "givenName": "Michael S.", 
            "id": "sg:person.01043211662.37", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01043211662.37"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Winter", 
            "givenName": "Greg", 
            "id": "sg:person.0655407005.55", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655407005.55"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1002/eji.1830080605", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003063608"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0014-5793(78)80145-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007280603"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0092-8674(81)90089-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009786716"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/eji.1830091216", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012260265"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/nar/12.1part2.521", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014933564"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.70.12.3305", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015139452"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-2836(85)90137-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016089018"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0378-1119(85)90120-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017120147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0378-1119(85)90120-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017120147"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/312643a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017996216", 
              "https://doi.org/10.1038/312643a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-2836(80)90252-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020340850"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.74.12.5463", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025360556"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/314268a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027818224", 
              "https://doi.org/10.1038/314268a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.81.21.6851", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030102558"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.78.2.1138", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034515223"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-2836(82)90179-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034884757"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0167-7799(84)90013-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038356460"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/312604a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047097780", 
              "https://doi.org/10.1038/312604a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0022-2836(83)80206-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048880754"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1073/pnas.71.11.4298", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049796763"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0378-1119(82)90016-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052252120"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0378-1119(82)90016-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052252120"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/314235a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053524488", 
              "https://doi.org/10.1038/314235a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/bi00342a025", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055171066"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1076396110", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1080007714", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1081610210", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/j.1460-2075.1982.tb01223.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1081635368"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/j.1460-2075.1982.tb01219.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1081948282"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1986-05", 
        "datePublishedReg": "1986-05-01", 
        "description": "The variable domains of an antibody consist of a beta-sheet framework with hypervariable regions (or complementarity-determining regions--CDRs) which fashion the antigen-binding site. Here we attempted to determine whether the antigen-binding site could be transplanted from one framework to another by grafting the CDRs. We substituted the CDRs from the heavy-chain variable region of mouse antibody B1-8, which binds the hapten NP-cap (4-hydroxy-3-nitrophenacetyl caproic acid; KNP-cap = 1.2 microM), for the corresponding CDRs of a human myeloma protein. We report that in combination with the B1-8 mouse light chain, the new antibody has acquired the hapten affinity of the B1-8 antibody (KNP-cap = 1.9 microM). Such 'CDR replacement' may offer a means of constructing human monoclonal antibodies from the corresponding mouse monoclonal antibodies.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1038/321522a0", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0090-0028", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6069", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "321"
          }
        ], 
        "name": "Replacing the complementarity-determining regions in a human antibody with those from a mouse", 
        "pagination": "522-525", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "2449443fa27aae8d0ea6c5aff7e7dd145f3a691f22eb03d481b7bdc7c50b2569"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "3713831"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "0410462"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/321522a0"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1007617918"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/321522a0", 
          "https://app.dimensions.ai/details/publication/pub.1007617918"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T19:45", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000422.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://www.nature.com/articles/321522a0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/321522a0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/321522a0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/321522a0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/321522a0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    223 TRIPLES      21 PREDICATES      69 URIs      34 LITERALS      22 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/321522a0 schema:about N179cbcde93e84130bb82a7bef7d093c8
    2 N1de564f85f0348949448acf81e610691
    3 N32f9920f941f4846b2a7f5527639bcb5
    4 N359de2535b354bc98d8c41e6d8da41a7
    5 N365b65cfa4e84012b29f5be52fd44886
    6 N4d1b896c86c44c28a5bd7455affedf7d
    7 N557ac7350c384deda3214f82e9bc8d21
    8 N79d9bd7eb7fd4f4eb385390f398fd877
    9 N892dfe9c850f47548655dd19a08a33b1
    10 Na7ce70b99c6b45a5a0a43f38e527c163
    11 Na8d2c8e9bb824ab6a341c380ecfd40d1
    12 Nbe07c00d51744b738c582fce5a76e37b
    13 Nee827c41fc0d400fb8c8a61a93f1fb94
    14 anzsrc-for:11
    15 anzsrc-for:1107
    16 schema:author N101a943e63c44161a2ad57f2f8dd5fd0
    17 schema:citation sg:pub.10.1038/312604a0
    18 sg:pub.10.1038/312643a0
    19 sg:pub.10.1038/314235a0
    20 sg:pub.10.1038/314268a0
    21 https://app.dimensions.ai/details/publication/pub.1076396110
    22 https://app.dimensions.ai/details/publication/pub.1080007714
    23 https://app.dimensions.ai/details/publication/pub.1081610210
    24 https://doi.org/10.1002/eji.1830080605
    25 https://doi.org/10.1002/eji.1830091216
    26 https://doi.org/10.1002/j.1460-2075.1982.tb01219.x
    27 https://doi.org/10.1002/j.1460-2075.1982.tb01223.x
    28 https://doi.org/10.1016/0014-5793(78)80145-8
    29 https://doi.org/10.1016/0022-2836(80)90252-1
    30 https://doi.org/10.1016/0022-2836(82)90179-6
    31 https://doi.org/10.1016/0022-2836(85)90137-8
    32 https://doi.org/10.1016/0092-8674(81)90089-1
    33 https://doi.org/10.1016/0167-7799(84)90013-1
    34 https://doi.org/10.1016/0378-1119(82)90016-6
    35 https://doi.org/10.1016/0378-1119(85)90120-9
    36 https://doi.org/10.1016/s0022-2836(83)80206-x
    37 https://doi.org/10.1021/bi00342a025
    38 https://doi.org/10.1073/pnas.70.12.3305
    39 https://doi.org/10.1073/pnas.71.11.4298
    40 https://doi.org/10.1073/pnas.74.12.5463
    41 https://doi.org/10.1073/pnas.78.2.1138
    42 https://doi.org/10.1073/pnas.81.21.6851
    43 https://doi.org/10.1093/nar/12.1part2.521
    44 schema:datePublished 1986-05
    45 schema:datePublishedReg 1986-05-01
    46 schema:description The variable domains of an antibody consist of a beta-sheet framework with hypervariable regions (or complementarity-determining regions--CDRs) which fashion the antigen-binding site. Here we attempted to determine whether the antigen-binding site could be transplanted from one framework to another by grafting the CDRs. We substituted the CDRs from the heavy-chain variable region of mouse antibody B1-8, which binds the hapten NP-cap (4-hydroxy-3-nitrophenacetyl caproic acid; KNP-cap = 1.2 microM), for the corresponding CDRs of a human myeloma protein. We report that in combination with the B1-8 mouse light chain, the new antibody has acquired the hapten affinity of the B1-8 antibody (KNP-cap = 1.9 microM). Such 'CDR replacement' may offer a means of constructing human monoclonal antibodies from the corresponding mouse monoclonal antibodies.
    47 schema:genre research_article
    48 schema:inLanguage en
    49 schema:isAccessibleForFree false
    50 schema:isPartOf N97ec3e085fa84179ae57359fc990fcb2
    51 Nb6e934891f8844acb1eb7e1880841ea0
    52 sg:journal.1018957
    53 schema:name Replacing the complementarity-determining regions in a human antibody with those from a mouse
    54 schema:pagination 522-525
    55 schema:productId N27ee36578ed94e878719ceebf5318c45
    56 N746b1dad218145ae8fbd9b1ad7d4a9e5
    57 N9c4956881e3b4700b3c14a9a34af6409
    58 Ndde15a81e517431d8ad0d1b9d20b1e4b
    59 Nfa3d5728e46e4f679ffcebaa2d4926eb
    60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007617918
    61 https://doi.org/10.1038/321522a0
    62 schema:sdDatePublished 2019-04-10T19:45
    63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    64 schema:sdPublisher Na3504e6a6f2047ef83789833e7ad2896
    65 schema:url http://www.nature.com/articles/321522a0
    66 sgo:license sg:explorer/license/
    67 sgo:sdDataset articles
    68 rdf:type schema:ScholarlyArticle
    69 N03284fe44f044d56bd7a666110fd1301 rdf:first sg:person.01317103576.22
    70 rdf:rest Nfc0e1436978540748352073bd6234d72
    71 N101a943e63c44161a2ad57f2f8dd5fd0 rdf:first sg:person.0630656334.35
    72 rdf:rest N5f7feeda74d945279df107f5acd44ef5
    73 N179cbcde93e84130bb82a7bef7d093c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    74 schema:name Immunoglobulin Variable Region
    75 rdf:type schema:DefinedTerm
    76 N1de564f85f0348949448acf81e610691 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    77 schema:name Immunoglobulin E
    78 rdf:type schema:DefinedTerm
    79 N27ee36578ed94e878719ceebf5318c45 schema:name pubmed_id
    80 schema:value 3713831
    81 rdf:type schema:PropertyValue
    82 N32f9920f941f4846b2a7f5527639bcb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    83 schema:name Mice
    84 rdf:type schema:DefinedTerm
    85 N359de2535b354bc98d8c41e6d8da41a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    86 schema:name Plasmids
    87 rdf:type schema:DefinedTerm
    88 N365b65cfa4e84012b29f5be52fd44886 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    89 schema:name Myeloma Proteins
    90 rdf:type schema:DefinedTerm
    91 N4d1b896c86c44c28a5bd7455affedf7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    92 schema:name Protein Conformation
    93 rdf:type schema:DefinedTerm
    94 N557ac7350c384deda3214f82e9bc8d21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    95 schema:name Animals
    96 rdf:type schema:DefinedTerm
    97 N5f7feeda74d945279df107f5acd44ef5 rdf:first sg:person.016667736115.82
    98 rdf:rest N03284fe44f044d56bd7a666110fd1301
    99 N746b1dad218145ae8fbd9b1ad7d4a9e5 schema:name readcube_id
    100 schema:value 2449443fa27aae8d0ea6c5aff7e7dd145f3a691f22eb03d481b7bdc7c50b2569
    101 rdf:type schema:PropertyValue
    102 N79d9bd7eb7fd4f4eb385390f398fd877 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    103 schema:name Models, Molecular
    104 rdf:type schema:DefinedTerm
    105 N8358e96df5814c98af3ecde14ea2f704 rdf:first sg:person.0655407005.55
    106 rdf:rest rdf:nil
    107 N892dfe9c850f47548655dd19a08a33b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    108 schema:name Base Sequence
    109 rdf:type schema:DefinedTerm
    110 N97ec3e085fa84179ae57359fc990fcb2 schema:volumeNumber 321
    111 rdf:type schema:PublicationVolume
    112 N9c4956881e3b4700b3c14a9a34af6409 schema:name nlm_unique_id
    113 schema:value 0410462
    114 rdf:type schema:PropertyValue
    115 Na3504e6a6f2047ef83789833e7ad2896 schema:name Springer Nature - SN SciGraph project
    116 rdf:type schema:Organization
    117 Na7ce70b99c6b45a5a0a43f38e527c163 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Amino Acid Sequence
    119 rdf:type schema:DefinedTerm
    120 Na8d2c8e9bb824ab6a341c380ecfd40d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Genes
    122 rdf:type schema:DefinedTerm
    123 Nb6e934891f8844acb1eb7e1880841ea0 schema:issueNumber 6069
    124 rdf:type schema:PublicationIssue
    125 Nbe07c00d51744b738c582fce5a76e37b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    126 schema:name Humans
    127 rdf:type schema:DefinedTerm
    128 Ndde15a81e517431d8ad0d1b9d20b1e4b schema:name dimensions_id
    129 schema:value pub.1007617918
    130 rdf:type schema:PropertyValue
    131 Nee827c41fc0d400fb8c8a61a93f1fb94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Species Specificity
    133 rdf:type schema:DefinedTerm
    134 Nfa3d5728e46e4f679ffcebaa2d4926eb schema:name doi
    135 schema:value 10.1038/321522a0
    136 rdf:type schema:PropertyValue
    137 Nfc0e1436978540748352073bd6234d72 rdf:first sg:person.01043211662.37
    138 rdf:rest N8358e96df5814c98af3ecde14ea2f704
    139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    140 schema:name Medical and Health Sciences
    141 rdf:type schema:DefinedTerm
    142 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    143 schema:name Immunology
    144 rdf:type schema:DefinedTerm
    145 sg:journal.1018957 schema:issn 0090-0028
    146 1476-4687
    147 schema:name Nature
    148 rdf:type schema:Periodical
    149 sg:person.01043211662.37 schema:familyName Neuberger
    150 schema:givenName Michael S.
    151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01043211662.37
    152 rdf:type schema:Person
    153 sg:person.01317103576.22 schema:familyName Foote
    154 schema:givenName Jefferson
    155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317103576.22
    156 rdf:type schema:Person
    157 sg:person.016667736115.82 schema:familyName Dear
    158 schema:givenName Paul H.
    159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016667736115.82
    160 rdf:type schema:Person
    161 sg:person.0630656334.35 schema:familyName Jones
    162 schema:givenName Peter T.
    163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0630656334.35
    164 rdf:type schema:Person
    165 sg:person.0655407005.55 schema:familyName Winter
    166 schema:givenName Greg
    167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655407005.55
    168 rdf:type schema:Person
    169 sg:pub.10.1038/312604a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047097780
    170 https://doi.org/10.1038/312604a0
    171 rdf:type schema:CreativeWork
    172 sg:pub.10.1038/312643a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017996216
    173 https://doi.org/10.1038/312643a0
    174 rdf:type schema:CreativeWork
    175 sg:pub.10.1038/314235a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053524488
    176 https://doi.org/10.1038/314235a0
    177 rdf:type schema:CreativeWork
    178 sg:pub.10.1038/314268a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027818224
    179 https://doi.org/10.1038/314268a0
    180 rdf:type schema:CreativeWork
    181 https://app.dimensions.ai/details/publication/pub.1076396110 schema:CreativeWork
    182 https://app.dimensions.ai/details/publication/pub.1080007714 schema:CreativeWork
    183 https://app.dimensions.ai/details/publication/pub.1081610210 schema:CreativeWork
    184 https://doi.org/10.1002/eji.1830080605 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003063608
    185 rdf:type schema:CreativeWork
    186 https://doi.org/10.1002/eji.1830091216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012260265
    187 rdf:type schema:CreativeWork
    188 https://doi.org/10.1002/j.1460-2075.1982.tb01219.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1081948282
    189 rdf:type schema:CreativeWork
    190 https://doi.org/10.1002/j.1460-2075.1982.tb01223.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1081635368
    191 rdf:type schema:CreativeWork
    192 https://doi.org/10.1016/0014-5793(78)80145-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007280603
    193 rdf:type schema:CreativeWork
    194 https://doi.org/10.1016/0022-2836(80)90252-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020340850
    195 rdf:type schema:CreativeWork
    196 https://doi.org/10.1016/0022-2836(82)90179-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034884757
    197 rdf:type schema:CreativeWork
    198 https://doi.org/10.1016/0022-2836(85)90137-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016089018
    199 rdf:type schema:CreativeWork
    200 https://doi.org/10.1016/0092-8674(81)90089-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009786716
    201 rdf:type schema:CreativeWork
    202 https://doi.org/10.1016/0167-7799(84)90013-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038356460
    203 rdf:type schema:CreativeWork
    204 https://doi.org/10.1016/0378-1119(82)90016-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052252120
    205 rdf:type schema:CreativeWork
    206 https://doi.org/10.1016/0378-1119(85)90120-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017120147
    207 rdf:type schema:CreativeWork
    208 https://doi.org/10.1016/s0022-2836(83)80206-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1048880754
    209 rdf:type schema:CreativeWork
    210 https://doi.org/10.1021/bi00342a025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055171066
    211 rdf:type schema:CreativeWork
    212 https://doi.org/10.1073/pnas.70.12.3305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015139452
    213 rdf:type schema:CreativeWork
    214 https://doi.org/10.1073/pnas.71.11.4298 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049796763
    215 rdf:type schema:CreativeWork
    216 https://doi.org/10.1073/pnas.74.12.5463 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025360556
    217 rdf:type schema:CreativeWork
    218 https://doi.org/10.1073/pnas.78.2.1138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034515223
    219 rdf:type schema:CreativeWork
    220 https://doi.org/10.1073/pnas.81.21.6851 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030102558
    221 rdf:type schema:CreativeWork
    222 https://doi.org/10.1093/nar/12.1part2.521 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014933564
    223 rdf:type schema:CreativeWork
     




    Preview window. Press ESC to close (or click here)


    ...